



## **Programs & Services Committee Agenda**

### **City of Newton** **In City Council**

**Tuesday, September 5, 2017**

**7:00PM – NOTE EARLY START**  
**Room 211**

#### **Items Scheduled for Discussion:**

- #261-17      Request to recognize September as Childhood Cancer Awareness Month**  
COUNCILOR LIPOF requesting the City Council and the City recognize September as Childhood Cancer Awareness Month. [008/11/17 @ 8:30 AM]
- #235-17      Mayor's appointment of Karl Munger to the Biosafety Committee**  
KARL MUNGER, 5 Nightingale Path, Newton, appointed as a member of the BIOSAFETY COMMITTEE for a term to expire September 30, 2020. (60 days 10/13/17) [07/12/17 @ 2:25 PM]
- #243-17      Mayor's appointment of Julie A. Norstrand to the Council on Aging**  
JULIE A. NORSTRAND, 44 Stearns Street, Newton, appointed as a COMMISSIONER of the NEWTON COUNCIL ON AGING for a term to expire September 30, 2020. (60 days 10/13/17) [08/02/17 @ 2:23 PM]
- #245-17      Mayor's appointment of Chryse Gibson to the Council on Aging**  
CHRYSE GIBSON, 19 Hampden Terrace, Newton, appointed as a COMMISSIONER of the NEWTON COUNCIL ON AGING for a term to expire September 30, 2020. (60 days 10/13/17) [08/02/17 @ 2:23 PM]
- #244-17      Mayor's appointment of Donna Murphy to the Council on Aging**  
DONNA MURPHY, 496 Commonwealth Avenue, Newton, appointed as a COMMISSIONER of the NEWTON COUNCIL ON AGING for a term to expire September 30, 2020. (60 days 10/13/17) [08/02/17 @ 2:23 PM]
- #236-17      Mayor's re-appointment of Edward Marple to the Biosafety Committee**  
EDWARD MARPLE, 12 Ohio Avenue, Newton, re-appointed as a member of the BIOSAFETY COMMITTEE for a term to expire September 30, 2019. (60 days 10/13/17) [07/12/17 @ 2:25 PM]

---

The location of this meeting is accessible and reasonable accommodations will be provided to persons with disabilities who require assistance. If you need a reasonable accommodation, please contact the City of Newton's ADA Coordinator, Jini Fairley, at least two business days in advance of the meeting: [jfairley@newtonma.gov](mailto:jfairley@newtonma.gov) or (617) 796-1253. The city's TTY/TDD direct line is: 617-796-1089. For the Telecommunications Relay Service (TRS), please dial 711.

**#237-17 Mayor's re-appointment of John J. Schwartz to the Biosafety Committee**  
JOHN J. SCHWARTZ, 200 Upland Road, Newton, re-appointed as a member of the BIOSAFETY COMMITTEE for a term to expire September 30, 2020. (60 days 10/13/17) [07/12/17 @ 2:25 PM]

**#242-17 Mayor's re-appointment of Dana Hanson as Library Trustee**  
DANA HANSON, 64 Kingswood Road, Newton, appointed as a LIBRARY TRUSTEE for a term to expire June 30, 2021. (60 days 10/13/17) [07/12/17 @ 2:25 PM]

*Clerk's Note: There is a recommendation to NAN the following item:*

**Referred to PS&T, Programs & Services, Public Facilities and Finance Committees**

**#59-17 Appropriate \$350,000 for construction of a Parks & Recreation/Police building**  
HIS HONOR THE MAYOR requesting authorization to appropriate three hundred fifty thousand dollars (\$350,000) from Overlay Surplus for the purpose of funding the construction of a new combined Parks & Recreation and Police Department facility to be located at the Elliot Street DPW yard. [02/17/17 @ 9:29 AM]

**Items not Scheduled for Discussion at this meeting:**

- #238-17 Mayor's appointment of Geline W. Williams as Library Trustee**  
GELINE W. WILLIAMS, 12 Hereford Road, Waban, appointed as a LIBRARY TRUSTEE for a term to expire June 30, 2020. (60 days 10/13/17) [07/12/17 @ 2:25 PM]
- #239-17 Mayor's appointment of Joshua Steirman as Library Trustee**  
JOSHUA STEIRMAN, 90 Atwood Avenue, Newtonville, appointed as a LIBRARY TRUSTEE for a term to expire June 30, 2022. (60 days 10/13/17) [07/12/17 @ 2:25 PM]
- #240-17 Mayor's appointment of Jean Notis-McConarty as Library Trustee**  
JEAN NOTIS-McCONARTY, 122 Temple Street, West Newton, appointed as a LIBRARY TRUSTEE for a term to expire June 30, 2020. (60 days 10/13/17) [07/12/17 @ 2:25 PM]
- #241-17 Mayor's appointment of Sharon Stout as Library Trustee**  
SHARON STOUT, 9 Elmwood Park, Newton appointed as a LIBRARY TRUSTEE for a term to expire June 30, 2020. (60 days 10/13/17) [07/12/17 @ 2:25 PM]
- #208-17 Proposal to place a nonbinding advisory question on the ballot**  
PETER HARRINGTON, ET AL., requesting that the following non-binding question be placed on the November 7, 2017 municipal ballot: "Do you support rezoning village centers to allow four- and five-story mixed-use buildings near public transit with retail on the first floor and apartments above, as the City is recommending to update Newton's Zoning Ordinance for future growth?" [07/03/17 @ 2:59 PM]
- A Public Hearing will be held on the following item on September 6<sup>th</sup>:*
- #137-17 Request to discuss and repeal Welcoming City ordinance**  
SANDE YOUNG ET AL. requesting discussion and to repeal Ordinance A-102, the Welcoming City ordinance, or put the ordinance before the voters in the next municipal election. [04/28/17 @ 11:57 AM]
- #138-17(2) Request to place question of new Charter on the November ballot**  
CITY CLERK requesting the City Council, as required by MGL 43B, Section 11, order the Newton Charter Commission's proposed new charter to be submitted to the voters of the City of Newton for their approval on the November 7, 2017 municipal ballot. The ballot question to read: "Shall the City of Newton approve the new home rule charter recommended by the Charter Commission as summarized below: Yes. No." [06/14/17 @ 2:42PM]

- #246-17      Citizens Petition requesting a resolution supporting later high school start time**  
JEFFREY PONTIFF ET AL. submitting a petition, pursuant to Section 10, Section 2 of the City of Newton Charter, requesting a Resolution from the City Council acknowledging the scientifically documented benefits of a later school time and supporting the Newton Public Schools to take action to delay high school start times.[07/28/17 @ 1:30 PM]
- #247-17      Citizens Petition requesting measures limiting City Council action to city issues**  
JANET STERMAN ET AL. submitting a petition, pursuant to Section 2 of the City of Newton Charter, for the City to adopt measures so that all new matters taken under discussion by the City Council pertain solely to the operation of the City; that all matters presented to the City Council pertaining to the operation of the Commonwealth of Massachusetts be referred to state Representatives and Senators representing the City of Newton; and that all matters pertaining to the operation of the United States federal government be referred to the United States Representatives and Senators representing Massachusetts. (90 days: 11/12/17) [07/31/17 @ 10:10 AM]
- #193-17      Rules amendment: Referral of business**  
CITY CLERK requesting a Rules amendment to Section 3, Referral of business to Committees, Item D by replacing the word “petition” in the first sentence with the words “docket item.” [06/09/17 @ 4:02PM]
- #194-17      Rescission of date and time notation on docket items**  
CITY CLERK requesting rescission of Council Order #369-06 ALD. JOHNSON requesting that all newly docketed items, when appearing on the new docket, shall include the date and time that the item was received by the Clerk’s office and the name of the clerk who received the item. [06/09/17 @ 4:02PM]
- #56-16      Ordinance amendment to add statutory references to policy on housing practices**  
COUNCILOR HESS-MAHAN requesting an amendment to Chapter 12, Section 50(b) *Policy of the city regarding housing practices*, to add statutory references to Title VI of the Civil Rights Act of 1964; the Americans with Disabilities Act; Section 504 of the Rehabilitation Act of 1973; the Age Discrimination Act; and any other applicable state or federal laws that were inadvertently omitted from the current ordinance. [02/08/16 @ 1:51 PM]
- #300-16      Ordinance to register lobbyists**  
COUNCILORS COTE, NORTON AND HARNEY proposing an ordinance to register lobbyists in the City of Newton. [08/10/16 @ 3:11 AM]
- #158-16      Ordinance to require notice on gas pumps relative to climate change**  
COUNCILORS NORTON AND SANGIOLO requesting an ordinance that requires a notice posted on retail gas station pumps within the City of Newton that informs

consumers that burning gasoline contributes to climate change; and a link to a City website page offering information regarding alternatives to gasoline powered transportation, including walking, biking, public transit and electric vehicles.  
[04/25/16 @ 9:02 AM]

**#31-15(6) Amendment to noise ordinance relative to leaf blowers**  
COUNCILOR LEARY proposing to amend Chapter 20, Restrictions on use of leaf blowers, to specify permitted hours of use of electric and battery powered leaf blowers from Memorial Day through Labor Day and to exclude, at all times, the use of gasoline or fuel-based generators to charge leaf blower batteries or to power electric leaf blowers. [03/13/17 @ 3:26PM]

**#34-13 Ordinance to prohibit polystyrene food/beverage containers**  
ALD. DANBERG, ALBRIGHT, BLAZAR, RICE, LINSKY AND CROSSLEY requesting a prohibition on polystyrene-based disposable food or beverage containers in the City of Newton if that packaging takes place on the premises of food establishments within the City. [01/03/13 @ 11:01 AM]

### **Referred to Programs & Services and Public Safety & Transportation Committees**

**#46-17 Discussion regarding how community policing works**  
COUNCILOR ALBRIGHT requesting a discussion with the Chief of Police and/or members of his department to explain to the City Council how “community policing” works in Newton, how it differs from traditional policing, how staffing differs from traditional departments, and how it benefits Newton. [02/20/17 @ 3:21 PM]

**#363-16 Amendment to the City Council Rules for yearly review of City Clerk’s salary**  
PRESIDENT LENNON AND VICE PRESIDENT LAPPIN requesting an amendment to Article XI of the Rules and Orders of the City Council to require an annual review of the salary of the City Clerk/Clerk of the Council. [10/26/16 @ 3:58 PM]

### **Referred to Programs & Services and Public Facilities Committees**

**#344-16 Discussion regarding oversight of all city/school buildings to improve efficiencies**  
COUNCILOR LAPPIN requesting a discussion regarding the Public Buildings Department overseeing all public buildings, including School Department facilities, to improve efficiencies. [10/07/16 @ 10:47 AM]

**#301-16 Amendment to the Tree Preservation Ordinance**  
COUNCILOR SANGIOLO requesting an amendment to the Tree Preservation Ordinance so that any tree removal requested by a city department be forwarded to the Urban Tree Commission and all tree removal requests under the Tree Preservation Ordinance be posted online to give residents and interested citizens notification. [08/09/16 @10:30 PM]

**#264-16 Ord. requiring Councilor notice of and involvement in street tree waiver requests**

COUNCILORS HESS-MAHAN, NORTON, KALIS, COTE, DANBERG, HARNEY, SANGIOLO, LEARY AND YATES requesting an ordinance requiring that Councilors from each respective ward be given notice and a meaningful opportunity to object to granting a hardship waiver or permit to remove a street tree. [07/21/16 @ 11:40 AM]

**Referred to Land Use, Programs & Services, and Finance Committees**

- #256-16**      **Request to extend notification area of notice for special permit petitions**  
COUNCILORS COTE, NORTON, HARNEY, BLAZER, BROUSAL-GLASER, AND LEARY requesting an amendment to the City Council Rules, Article X; Section 6 – Additional Notification Requirements, to include that the area of notice for special permit petitions be expanded beyond the abutters to abutters within 300' required by Massachusetts General Law Chapter 40A to also include property owners within 600' of the subject property. This notification will apply to all classes of building except for residential 1 and 2-family units that will remain 1 or 2-family units after receiving a special permit. Only abutters to abutters within 300' will be entitled to the rights conferred by Massachusetts General Law Chapter 40A [07/01/16 @2:09 PM]

**Referred to Programs & Services and Public Facilities Committees**

- #141-15**      **Discussion on tracking the gas utility infrastructure in Newton**  
ALD. BROUSAL-GLASER, SANGIOLO, HESS-MAHAN, COTE, NORTON AND ALBRIGHT requesting a discussion with *the Director of Urban Forestry*, a representative of the Department of Public Works and a representative of the Law Department about tracking and improving the condition of the gas utility infrastructure in Newton, new state statutes governing infrastructure repairs, coordination of increased repair work with city operations, the status of negotiations with National Grid to compensate for tree deaths resulting from gas leaks, and the possibility of creating a utilities working group to monitor progress on these and related issues. 05/26/15 @ 2:53 PM]

**Referred to Programs & Services and Public Facilities Committees**

- #201-15**      **Discussion of the condition of the Kennard Estate on Dudley Road**  
ALD. SANGIOLO requesting a discussion with the Commissioner of Public Buildings, the Commissioner of Parks and Recreation, and the Executive Department regarding the condition of the property located at 246 Dudley Road (Kennard Estate) and how much, if any, repairs and upgrades will be needed as the City relocates the Parks and Recreation Department to that location. [09/01/15 @ 4:00 PM]
- #483-14**      **Resolution to promote cooperative programs with food establishments**  
PROGRAMS & SERVICES COMMITTEE proposing a RESOLUTION to promote a cooperative program with food establishments in the City, the Newton-Needham Chamber of Commerce, the Economic Development Commission, the Director of

Economic Development and members of the Board of Aldermen, to find opportunities for these establishments to provide their food services for events in the City. [12/02/14 @ 3:56 PM]

**Referred to Programs & Services and Finance Committees**

**#216-14**

**Ordinance amendment for notification of vacancy of unit and/or condo conversion**

**ALD. HESS-MAHAN, ALBRIGHT, BAKER, CROSSLEY, NORTON AND SANGIOLO**

proposing the following amendments to Chapter 12 Health and Human Services of the Revised Ordinances to:

- require owners of dwellings requiring a Certificate of Habitability under Section 12-1 and real estate agents/brokers who receive compensation in connection with the particular real estate transaction to notify the Commissioner of Health and Human Services whenever an apartment, tenement, or room in a lodging house is vacated by the occupant or when an area in an existing building is converted to a condominium prior to being reoccupied by a new tenant, lodger or occupant;
  - require educational institutions to disclose addresses of undergraduates living off-campus in Newton;
  - require a fee for certification; and
  - impose a fine for violation of these provisions. [05/14/14 @11:51 AM]
- FINANCE VOTED NO ACTION NECESSARY 7-0 12/14/15

**#398-13**

**Discussion of complementary ordinance or regulations for Marijuana Dispensaries**

**ALD. BAKER & DANBERG** requesting a discussion of a possible ordinance, regulations or otherwise, to complement zoning regulation of any licensed Registered Marijuana Dispensaries to respond to any secondary impacts so as to make the operation of such dispensaries as successful as possible. [10/28/13 @ 10:00 AM]

**UPDATE ITEMS:**

**Referred to Programs & Services Committees and Public Facilities**

**#12-17**

**Request for updates on the Library Expansion Project**

**COUNCILORS CROSSLEY, ALBRIGHT AND BLAZAR** requesting periodic updates from the Library Trustees and Library Director on the Library expansion project. [01/03/2017 @ 3:55 PM]

**Referred to Programs & Services Committees and Public Facilities**

**#13-17**

**Request for updates on the Archive Expansion Project**

**COUNCILORS CROSSLEY, ALBRIGHT, AND BLAZAR** requesting periodic updates from the City Clerk on the Archives expansion project. [01/03/2017 @ 3:56 PM]

**Referred to Programs & Services and Public Facilities Committees**

- #27-16      Updates from the Administration on the renovations at the Aquinas site**  
PROGRAMS & SERVICES AND PUBLIC FACILITIES COMMITTEES requesting that the School Department and/or Executive Department provide updates on removal of asbestos and other toxic materials that were identified at the Aquinas site, the scope and timing of window replacement in particular, and renovations that may be necessary to facilitate short and long-term plans for uses and operations at the site. [01/10/16 @ 1:14 PM]

**Referred to Programs & Services and Public Safety & Transportation Committees**

- #312-15      Update from Health Department on opiate overdose epidemic**  
ALD. COTE, HARNEY AND NORTON, requesting a review and discussion of the opiate overdose epidemic including an update from the Health Department appraising the board on the current situation to include comparative statistics from previous years as to the number of opiate overdoses handled by first responders. In addition, what is being done immediately to take this on and what support can the Board provide
- #377-14      Discussion of proposed changes of use of the Senior Center**  
THE PROGRAMS & SERVICES COMMITTEE requesting a discussion with the Director of Senior Services, the Council on Aging and the Executive Department relative to changes in the use of the Senior Center at 345 Walnut Street. [10/16/14 @ 5:43 PM]

**Referred to Programs & Services and Public Facilities Committees**

- #119-14      Update from Inspectional Services on ADA compliance of City properties**  
ALD. ALBRIGHT AND CROSSLEY requesting discussion with the Inspectional Services Department to explain the development of short and long term plans to identify and correct buildings, sidewalks, playgrounds, etc., that do not conform to American Disability Act (ADA) standards. The discussion should include information on how improvements will be incorporated into the Capital Improvement Plan or if less than \$75,000 into a comprehensive budget plan to correct ADA deficiencies. [03/12/14 @ 4:18 PM]

**Respectfully Submitted,**

**John B. Rice, Chair**



CITY OF NEWTON

IN CITY COUNCIL

September 5, 2017

RESOLUTION

RECOGNIZING SEPTEMBER AS CHILDHOOD CANCER AWARENESS MONTH

BE IT RESOLVED:

WHEREAS, Childhood Cancer is the leading disease killer and second leading cause of death of children under the age of 15 in the United States; and

WHEREAS, more than 15,000 children are diagnosed with some form of cancer annually and approximately one-quarter of them will not survive the disease; and

WHEREAS, there exists the need to bring attention to the types of cancer that most impact children, to recognize the impact such a diagnosis has on entire families and caregivers and to encourage research and family support;

THEREFORE, BE IT RESOLVED, that the NEWTON CITY COUNCIL recognizes the month of September as Childhood Cancer Awareness Month and reaffirms its commitment to increase awareness and provide support to the children and families who have suffered loss and those who face childhood cancer today.

Under Suspension of Rules  
Readings Waived and Approved  
yeas    nays

(SGD) DAVID A. OLSON  
City Clerk



SETTI D. WARREN  
MAYOR

City of Newton, Massachusetts  
Office of the Mayor

#235-17

Telephone  
(617) 796-1100

Facsimile  
(617) 796-1113

TDD/TTY  
(617) 796-1089

E-mail  
swarren@newtonma.gov

Honorable City Council  
Newton City Hall  
1000 Commonwealth Avenue  
Newton, MA 02459

Ladies and Gentlemen:

I am pleased to appoint Karl Munger of 5 Nightingale Path, Newton as a member of the Biosafety Committee. His term of office shall expire on September 30, 2020 and his appointment is subject to your confirmation.

Thank you for your attention to this matter.

Very truly yours,

  
Setti D. Warren

Mayor

RECEIVED  
Newton City Clerk  
2017 JUL 12 PM 2:25  
David A. Olson, Clerk  
Newton, MA 02459

1000 Commonwealth Avenue Newton, Massachusetts 02459

[www.newtonma.gov](http://www.newtonma.gov)



DEDICATED TO COMMUNITY EXCELLENCE

## BIOGRAPHICAL SKETCH - RESUME

Karl Munger, Ph.D.  
5 Nightingale Path  
Newton, MA 02459

Professor  
Department of Developmental, Molecular and Chemical Biology  
150 Harrison Avenue  
Jaharis 607  
Boston MA 02111

### Summary

Accomplished academic researcher with over 25 years of experience as an independent biomedical researcher. Over 20 years of uninterrupted research funding from the National Cancer Institute/National Institutes of Health. Made seminal discoveries on how human papillomaviruses (HPVs) cause cancer. Published over 200 scientific articles that have been cited almost 30,000 times, resulting in Hirsh factor of 75. Invited as a lecturer to national and international conferences, and academic and non-academic research institutions. Organizer of scientific conferences, editor of multiple scientific journals, and experienced reviewer of research grant applications to the National Institutes of Health, American Cancer Society and many other regional, national and international funding agencies. Gifted teacher and mentor to undergraduate and graduate students as well as postdoctoral fellows and junior faculty. Director of outreach programs for underrepresented minority students.

### Education and Training

1976-1981 B.Sc. ("Diplom"), Department of Biochemistry, Zürich University, Zürich Switzerland.  
1981-1986 Ph.D. ("Dr. phil II"), Department of Biochemistry, University of Zürich, Zürich, Switzerland.  
1986-1990 Postdoctoral Fellow, Laboratory of Tumor Virus Biology, NCI, NIH, Bethesda, MD.

### Positions

1990-1993 Visiting Associate, Laboratory of Tumor Virus Biology, NCI, NIH, Bethesda, MD.  
1993-1998 Assistant Professor, Department of Pathology, Harvard Medical School, Boston, MA.  
1998-2005 Associate Professor, Department of Pathology, Harvard Medical School, Boston, MA.  
2005-2013 Associate Professor of Medicine, Harvard Medical School, Boston, MA.  
2013-2014 Professor of Medicine, Harvard Medical School, Boston, MA.  
2014- Professor, Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA.

### Awards and Honors

1986-1988 John E. Fogarty Postdoctoral Fellowship, National Institutes of Health.  
1989 Advanced Training Fellowship, Swiss National Science Foundation.  
1990 Dr. Ernst Th. Jucker Award for Experimental Cancer Research, University of Zurich, Switzerland.  
1996-1998 Junior Faculty Research Award, American Cancer Society.  
1996, 2007 Visiting Professor, Department of Biology, University of Padua, Italy.  
1998 Hauck Lectureship, Mayo Clinic Cancer Center, Rochester, MN.

- 1998-2000 Ludwig Fellowship, Virginia and D.K. Ludwig Fund for Cancer Research.  
 2004 McKelvey Lectureship in Gynecologic Pathology, University of Minnesota, Minneapolis, MN.  
 2005-2007 Visiting Scientist, G. R. Harrison Spectroscopy Laboratory, MIT, Cambridge, MA.  
 2010 Visiting Professor, Lombardi Comprehensive Cancer Center, Washington, DC.  
 2010 Pfitzer Lecture, Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Canada.  
 2013 Master of Arts (Hon), Harvard University, Cambridge, MA.  
 2015 Fellow, American Academy of Microbiology (elected).

### Professional Activities

- 1995-present Editorial Board, *Journal of Virology*.  
 1995-present Editorial Board, *Virology*.  
 1996-present Member, Various Scientific Review Groups and Special Emphasis Panels at the National Institutes of Health (NIH).  
 1996, 2007 Visiting Professor, Department of Biology, University of Padua, Italy.  
 1996, 99, 2005, 07, 09, 10, 11, 14 Scientific Advisory Committee, International Papillomavirus Conference.  
 1998, 2000, 08, 10 Organizing Committee, Small DNA Tumor Virus Conference.  
 1998, 2006 Section Chair, Program Committee, AACR, Annual Meetings.  
 2003, 04 Program Committee, AACR, Annual Meetings.  
 2006 Nominating Committee, Kirk A. Landon-AACR Prize for Basic Cancer Research.  
 2012 Co-Chair, Basic Science Track, 28<sup>th</sup> International Papillomavirus Conference.  
 2000-2004 Regular Member, Virology Scientific Review Group, NIH.  
 2001-2009 Associate Editor, *Cancer Research*.  
 2001-present Associate Editor, *Cancer Biology and Therapy*.  
 2004-2009 Member, MGO Study Section, American Cancer Society.  
 2005 Visiting Scientist, GR Harrison Spectroscopy Laboratory, MIT, Cambridge, MA.  
 2005-present Editorial Board, *International Journal of Cancer*.  
 2005-2008 Editor-in-Chief, *Molecular Cancer*.  
 2006, 07, 14 Member, Cellular and Molecular Biology P01 Cluster Review Panel (NCI).  
 2006-2014 Faculty Co-Director of Diversity Programs, DMS, Harvard Medical School, Boston, MA.  
 2007, 11 Member, Site Visit Team, German Cancer Research Center (DKFZ), Heidelberg, Germany.  
 2008-present Section Editor, *PLOS Pathogens*.  
 2008-2011 Regular Member, Virology B Scientific Review Group, NIH.  
 2010-present Editorial Board, *Genes & Cancer*  
 2015-present Editorial Board, *Signal Transduction and Targeted Therapy*  
 2016-present Director, Building Diversity in Biomedical Sciences Program, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine.

### Selected Invited Lectures/Conferences

- 2016 Department of Biology, University of Puerto Rico at Cayey, Puerto Rico  
 2016 AACR Special Conference: "The Cancer Cell Cycle: Tumor Progression and Therapeutic Response", Orlando FL  
 2016 Department of Otolaryngology/Head & Neck Surgery, University of Michigan, Ann Arbor, MI  
 2016 Institute of Technology, University of Tartu, Estonia  
 2016 3<sup>rd</sup> Macau Symposium on Biomedical Sciences 2016, Macau, PRC  
 2016 4<sup>th</sup> Emerging Oncogenic Viruses Conference, San Pietro in Bevagna, Puglia, Italy

- 2016 Small DNA Tumor Virus Conference, Montreal, Canada
- 2016 "Mechanistic Understanding of Cervical Carcinogenesis" NCI workshop, Shady Grove MD
- 2017 31<sup>st</sup> International Papillomavirus Conference (HPV 2017), Cape Town, South Africa
- 2017 3<sup>rd</sup> Annual New England Regional SACNAS Conference, Boston, MA
- 2017 "Viruses and Cells", Gordon Research Conference, Il Ciocco, Lucca (Barga), Italy
- 2017 Department of Molecular Microbiology & Immunology, University of Southern California Keck School of Medicine, Los Angeles, CA
- 2017 University of Arizona Cancer Center, Cancer Biology Lecture Series, Tuscan AZ
- 2017 Viral Manipulation of Nuclear Processes Conference, Charleston, SC

**Selected Publications** (total publications, 200; total citations, 29508; h-index, 75)

Harden ME, **Munger K**. Human papillomavirus molecular biology. *Mutat Res*. 2017; 772:3-12. PMID: 28528688.

Meyers JM, **Munger K**. The viral etiology of skin cancer. *J Invest Dermatol*. 2014; 134:E29-32. PMID: 25302471.

Mesri EA, Feitelson MA, **Munger K**. Human viral oncogenesis: a cancer hallmarks analysis. *Cell Host Microbe* 2014; 15:266-82. PMID: 24629334; PMCID: PMC3992243.

Roman A, **Munger K**. The papillomavirus E7 proteins. *Virology*. 2013;445:138-68. PMID: 23731972; PMCID: PMC3783579.

**Links to (more) complete bibliographical data**

[https://scholar.google.com/citations?user=liB-o\\_oAAAAJ&hl=en](https://scholar.google.com/citations?user=liB-o_oAAAAJ&hl=en)

<http://www.ncbi.nlm.nih.gov/myncbi/karl.munger.2/bibliography/40438593/public/?sort=date&direction=ascending>

## Bibliography (04/2017)

Citations	29041
h-index	74
i10-index	141

1. Münger K, Lerch K, Tschierpe HJ. Metal accumulation in *Agaricus bisporus*: influence of Cd and Cu on growth and tyrosinase Activity, *Experientia* 1982;38:1039-41.
2. Münger K, Germann UA, Beltramini M, Niedermann D, Baitella-Eberle G, Kägi JHR, Lerch K. (Cu/Zn) Metallothioneins from fetal bovine liver: chemical and spectroscopic properties, *J. Biol. Chem.* 1985;260:10032-38.
3. Münger K, Germann UA, Lerch K. Isolation and structural organization of the *Neurospora crassa* copper metallothionein gene, *EMBO J.* 1985;4:2665-68.
4. Münger K, Lerch K. Copper metallothionein from the fungus *Agaricus bisporus*: chemical and spectroscopic properties, *Biochemistry* 1985;24:6751-56.
5. Münger K, Germann UA, Lerch K. The *Neurospora crassa* copper metallothionein gene: regulation of expression and chromosomal location, *J. Biol. Chem.* 1987;262:7363-67.
6. Moser R, Frey S, Münger K, Hehlhans T, Klauser S, Langen H, Winnacker E-L, Mertz R, Gutte B. Expression of the synthetic gene of an artificial DDT-binding polypeptide in *E. coli*, *Protein Engineering* 1987;1:339-47.
7. Münger K, Germann UA, Lerch K. Isolation and regulation of expression of the *Neurospora crassa* copper metallothionein gene, *Experientia Suppl.* 1987;52:393-400.
8. Beltramini M, Münger K, Germann UA, Lerch K. Luminescence emission from the Cu(I) thiolate complex in metallothioneins, *Experientia Suppl.* 1987;52:237-42.
9. Münger K, Lerch K. Peptide mapping of vertebrate and invertebrate metallothioneins, *Inorganica Chimica Acta* 1988;151:11-3.
10. Phelps WC, Yee CL, Münger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to adenovirus E1a, *Cell* 1988;53:339-47.
11. Beltramini M, Giacometti GM, Salvato B, Giacometti G, Münger K, Lerch K. Luminescence emission from *Neurospora* copper metallothionein: Time-resolved Studies, *Biochem. J.* 1989;260:189-93.
12. Münger K, Germann UA, Beltramini M, Kupper U, Lerch K. *Neurospora* copper metallothionein: molecular structure and gene expression, *UCLA Symp. Mol. Cell. Biol.* 1989;98:227-35.

13. Dyson N, Howley PM, Münger K, Harlow E. The human papillomavirus type 16 E7 oncoprotein is able to bind the retinoblastoma gene product, *Science* 1989;243:934-7.
14. Münger K, Phelps WC, Bubbs V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes, *J. Virol.* 1989;63:4417-21.
15. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product, *EMBO J.* 1989;8:4099-105.
16. Phelps WC, Münger K, Yee CL, Schlegel R, Howley PM. Human genital papillomaviruses: transcriptional regulation and transformation. In: *Common mechanisms of transformation by small DNA tumor viruses*, (LP Villareal, ed), ASM Publications, Washington DC 1989, pp 149-64.
17. Phelps WC, Yee CL, Münger K, Howley PM. Functional and sequence similarities between HPV16 E7 and adenovirus E1A, *Current Topics Microbiol. Immunol.* 1989;144:153-66.
18. Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM, Pittelkow MR, Münger K, Howley PM, Moses HL. TGF $\beta$ 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains, *Cell* 1990;61:777-85.
19. Münger K, Phelps WC, Bubbs V, Howley PM, Schlegel R. Keratinocyte transformation by the HPV-16 E6 and E7 genes progresses through two distinct morphological stages, *UCLA Symp. Mol. Cell. Biol.* 1990;124:223-30.
20. Münger K, Phelps WC, Howley PM. Human papillomaviruses and neoplastic transformation, *Bristol Myers Cancer Symp.* 1990;11:223-54.
21. Cowser LM, Münger K, Howley PM, Baker CC. The E6-E7 region of HPV-16 is sufficient for altered differentiation of human keratinocytes, *UCLA Symp. Mol. Cell. Biol.* 1990;124:265-70.
22. Phelps WC, Münger K, Yee CL, Howley PM. Site directed mutagenesis of the HPV-16 E7 protein, *UCLA Symp. Mol. Cell. Biol.* 1990;124:305-11.
23. Howley PM, Münger K, Werness BA, Phelps WC, Schlegel R. Molecular mechanisms of transformation by the human papillomaviruses. In: *Genetic basis for carcinogenesis: tumor suppressor genes and oncogenes* (AG Knudson Jr, et al, eds) Japan Sci. Soc. Press Tokyo/Taylor & Francis Ltd London 1990, pp 199-206.
24. Münger K, Yee CL, Phelps WC, Pietenpol JA, Moses HL, Howley PM. Biochemical and biological differences between E7 oncoproteins of the high and low-risk HPVs are determined by amino terminal sequences, *J. Virol.* 1991;65:3943-8.

25. Scheffner M, Münger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines, *Proc. Natl. Acad. Sci. USA* 1991;88:5523-7.
26. Phelps WC, Bagchi S, Barnes J, Raychaudhuri P, Krause V, Münger K, Howley PM, Nevins JR. Analysis of trans-activation by HPV-16 E7 and adenovirus 12S E1A suggests a common mechanism, *J. Virol.* 1991;65:6922-30.
27. Pietenpol JA, Münger K, Howley PM, Stein RW, Moses HL. A factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor  $\beta$ -1 and by the retinoblastoma gene product, *Proc. Natl. Acad. Sci. USA* 1991;88:10227-31.
28. Münger K, Werness BA, Cowser LM, Phelps WC. Papillomaviruses and neoplastic transformation. In: *Encyclopedia of human biology vol 5* (R Dulbecco, ed), Academic Press 1991, pp 635-43. Second edition has been published.
29. Werness BA, Münger K, Howley PM. The role of the human papillomavirus oncoproteins in transformation and carcinogenic progression. In: *Important Advances in Oncology 1991* (VT deVita Jr, S Hellman, S Rosenberg eds), J.B. Lippincott Company, Philadelphia PA 1991, pp 3-18
30. Phelps WC, Münger K, Yee CL, Barnes JA, Howley PM. Structure-function analysis of the HPV16 E7 oncoprotein, *J. Virol.* 1992;66:2418-27.
31. Münger K, Pietenpol JA, Pittelkow MR, Holt JT, Moses HL. Transforming growth factor  $\beta$ 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes, *Cell Growth & Differentiation* 1992;3:291-8.
32. Chellappan S, Kraus VB, Kroger B, Münger K, Howley PM, Phelps WC, Nevins JR. E1A, T antigen and E7 share the capacity to disrupt the E2F-Rb interaction: implications for viral replication and the generation of human tumors, *Proc. Natl. Acad. Sci. USA* 1992;89:4549-53.
33. Heck DV, Yee CL, Howley PM, Münger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses, *Proc. Natl. Acad. Sci. USA* 1992;89:4442-6.
34. Scheffner M, Münger K, Huibregtse JM, Howley PM. Targeted degradation of the retinoblastoma protein by a fusion of the human papillomavirus E6 and E7 oncoproteins, *EMBO J.* 1992;11:2425-31.
35. Dyson N, Guida P, Münger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins, *J. Virol.* 1992;66:6893-902.
36. Howley PM, Scheffner M, Huibregtse JM, Münger K. The oncoproteins encoded by the cancer associated human papillomaviruses target the products of the retinoblastoma and p53 tumor suppressor genes, *CSH Symp. Quant. Biol.* 1992;LVI:149-55.



37. Murphy CS, Pietenpol JA, Münger K, Howley PM, Moses HL. C-MYC and pRB: role in TGF $\beta$ 1 inhibition of keratinocyte proliferation, CSH Symp. Quant. Biol. 1992;LVI:129-35.
38. Moses HL, Pietenpol JA, Münger K, Murphy CS, Yang EY. TGF $\beta$  regulation of epithelial cell proliferation: role of tumor suppressor genes. In: Multistage carcinogenesis (CC Harris et al, eds) Japan Sci. Soc. Press, Tokyo/CRC Press, Boca Raton 1992, pp 183-95.
39. Howley PM, Münger K, Romanczuk H, Scheffner M, Huibregtse JM. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. In: Multistage carcinogenesis (CC Harris et al, eds) Japan Sci. Soc. Press, Tokyo/CRC Press, Boca Raton 1992, pp 239-48.
40. Münger K, Scheffner M, Huibregtse JM, Howley PM. The interactions of the HPV E6 and E7 oncoproteins with tumor suppressor products, Cancer Surveys 1992;12:197-217
41. Wu EW, Clemens KE, Heck DV, Münger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein, J. Virol. 1993;67:2402-7.
42. Arbeit JM, Münger K, Howley PM, Hanahan D. Neuroepithelial carcinomas in mice transgenic with human papillomavirus type 16 E6/E7 ORFs, Am. J. Pathol. 1993;142:1187-97.
43. Scheffner M, Münger K, Huibregtse JM, Mietz JA, Howley PM. Interaction of the HPV E6 and E7 oncoproteins with the tumor suppressor proteins p53 and pRB. In: Precancerous lesions: a multidisciplinary approach (Series: Challenges of modern medicine, 1993) (PA Marks, H Turler, R Weil, eds) Ares-Serono Symposia Publications, Rome Italy 1993, pp 177-89.
44. Münger K, Phelps WC. The human papillomavirus E7 protein as a transforming and transactivating factor, Biochem. Biophys. Acta 1993;1155:111-23
45. Arbeit JM, Münger K, Howley PM, Hanahan D. Progressive squamous epithelial neoplasia in K14-HPV16 transgenic mice, J. Virol. 1994;68:4358-68.
46. Brokaw JL, Yee CL, Münger K. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein, Virology 1994;205:603-7.
47. Scheffner M, Romanczuk H, Münger K, Huibregtse JM, Mietz JA, Howley PM. Functions of HPV proteins, Current Topics Microbiol. Immunol. 1994;186:83-99
48. Clemens K, Brent R, Gyuris J, Münger K. Dimerization of the HPV E7 oncoprotein in vivo, Virology 1995;241:289-93.
49. Münger K. The molecular biology of cervical cancer, J. Cell. Biochem. 1995;23 (Suppl):55-60.

50. Human Papillomaviruses, IARC monographs on the evaluation of carcinogenic risks to humans; Volume 64. ISBN 92 832 1264 9. IARC/WHO Press, Lyon France 1995.
51. Münger K. Host-viral gene interactions in cervical cancer, *Contemp. OB/GYN* 1995;40:27-37
52. Jones DL, Münger K. Interactions of the human papillomavirus E7 protein with cell cycle regulators, *Sem. Cancer Biol.* 1996;7:327-37
53. Timmermann S, Hinds P, Münger K. Elevated activity of cyclin-dependent kinase 6 in oral carcinomas, *Cell Growth & Differentiation* 1997;8:361-70.
54. Jones DL, Münger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein, *J. Virol.* 1997;71:2905-12.
55. Oettgen P, Alani RM, Barcinski M, Akbarali Y, Boltax J, Brown L, Kunsch C, Münger K, Liberman TA. Isolation and characterization of a novel epithelial-specific transcription factor, ESE-1, a member of the ets family, *Mol. Cell. Biol.* 1997;17:4419-33.
56. Jones DL, Alani RM, Münger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21<sup>Cip1</sup>-mediated inhibition of cdk2, *Genes & Development* 1997;11:2101-11.
57. Mavromatis KO, Jones DL, Muherjee R, Yee C, Grace M, Münger K. The carboxyl terminal zinc-binding domain of the human papillomavirus E7 protein can be functionally replaced by the homologous sequences of the E6 protein, *Virus Research* 1997;52:109-18.
58. Thompson DA, Belinsky G, Chang TH-T, Jones DL, Schlegel R, Münger K. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints, *Oncogene* 1997;15:3025-36.
59. Jones DL, Thompson DA, Münger K. Destabilization of the pRB tumor suppressor protein and stabilization of p53 contribute to HPV type 16-induced apoptosis, *Virology* 1997;239:97-107.
60. Schilling B, De-Medina T, Syken J, Vidal M, Münger K. A novel human DnaJ protein, hTid-1, a homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein, *Virology* 1998;247:74-85.
61. Alani RM, Hasskarl J, Münger K. Alterations of cyclin-dependent kinase 2 function during differentiation of primary human keratinocytes, *Molecular Carcinogenesis* 1998;23:226-33.

62. Timmermann S, Hinds PH, Münger K. Reexpression of endogenous p16<sup>ink4a</sup> in oral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine induces a senescence-like state, *Oncogene* 1998;17:3445-53.
63. McBride AA, Androphy E, Münger K. Regulation of the papillomavirus E6 and E7 oncoproteins by the viral E1 and E2 proteins. In: *Viral regulatory structures and their degeneracy* (G Myers et al eds) Santa Fe institute studies in the science of complexity, vol XXVIII, Addison-Wesley 1998, pp 35-52.
64. Alani RM, Münger K. Human papillomaviruses and associated malignancies, *J. Clinical Oncol.* 1998;16:330-7.
65. Alani RM, Münger K. Human papillomaviruses, *Science & Medicine* 1998;5:28-35.
66. Jones DL, Thompson DA, Suh-Bürgmann E, Grace M, Münger K. Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent DNA damage response pathway, *Virology* 1999;258:406-14.
67. Syken J, De-Medina T, Münger K. hTid-1, the human homolog of the Drosophila tumor suppressor Tid56, is a mitochondrial regulator of apoptosis, *Proc. Natl. Acad. Sci. USA* 1999;96:8499-506.
68. Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA, Münger K. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id1, *Proc. Natl. Acad. Sci. USA* 1999;96:9637-641.
69. Oettgen P, Kas K, Dube A, Gu X, Grall F, Thamrongsak U, Akbarali Y, Finger E, Boltax J, Endress G, Münger K, Kunsch C, Libermann TA. Characterization of ESE-2, a novel ESE-1-related ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes. *J. Biol. Chem.* 1999;274:29439-52.
70. Howley PM, Münger K. Human papillomaviruses and squamous-cell carcinomas. In: *Microbes and malignancy* (JA Parsonnet, ed) Oxford University Press, New York/Oxford 1999, pp 157-79.
71. Münger K, Heselmeyer K. The molecular pathogenesis of cervical cancer: The role of human papillomaviruses. In: *Molecular Pathology of Early Cancer* (S Srivastava et al, eds) IOS Press, Amsterdam 1999, pp 97-111
72. Park JS, Boyer S, Mitchell K, Gilfor D, Birrer M, Darlington G, El Deiry W, Firestone GL, Münger K, Band V, Fisher PB, Dent P. Expression of human papillomavirus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21(Cip-1/WAF1/MDA6), *J Biol Chem* 2000;275:18-28.
73. Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Münger K. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle, *Proc. Natl. Acad. Sci USA* 2000;97:10002-7.

74. Wong DTW, Munger K. Association of human papillomaviruses with a subgroup of head and neck squamous cell carcinoma, *J. Natl. Cancer Inst.* 2000;92:675-7.
75. Munger, K. Learning old tricks from new viruses, *Nature Med* 2000;6:1091-2
76. Duensing S, Duensing A, Crum CP, Munger K. Human papillomavirus type 16 E7 oncoprotein induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype, *Cancer Res.* 2001;61:2356-60.
77. Thompson DA, Zacny V, Belinsky GS, Classon M, Jones DL, Schlegel R, Munger K. The HPV E7 oncoprotein abrogates tumor necrosis factor- $\alpha$ -mediated pro-caspase 8 activation and apoptosis in normal human fibroblasts, *Oncogene* 2001;20:3629-40.
78. Basile JR, Zacny V, Munger K. The cytokines TNF- $\alpha$  and TRAIL differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the HPV-16 E7 oncoprotein, *J. Biol. Chem.* 2001;276:22522-28.
79. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K, Crum CP. Ki-67, cyclin E and p16<sup>INK4A</sup> are complimentary surrogate biomarkers for human papillomavirus-related cervical neoplasia, *Am J Surg Pathol* 2001;25:884-91.
80. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7, *J. Virol.* 2001;75:7583-91.
81. Duensing S, Duensing A, Flores ER, Do A, Lambert PF, Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes, *J. Virol.* 2001;75:7712-16.
82. Jiang X, Wilford C, Duensing S, Munger K, Jones G, Jones D. Participation of survivin in mitotic and apoptotic activities of normal and tumor-derived cells, *J Cell Biochem* 2001;83:342 -54.
83. Duensing S, Munger K: Centrosome abnormalities, genomic instability and carcinogenic progression. *Biochim Biophys Acta* 2001;1471:M81-8.
84. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. Biological Activities and Molecular Targets of the Human Papillomavirus E7 Oncoprotein, *Oncogene* 2001;20:7888-98
85. Piboonniyom S, Timmermann S, Hinds P, Munger K. Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity, *Oral Onc* 2002;38:179-86.

86. Eichten A, Westfall M, Pietenpol JA, Münger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein, *Virology* 2002;295:74-85.
87. Duensing S, Münger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability, *Cancer Res.* 2002;62:7075-82.
88. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions, *Virus Res*, 2002;89: 213-28.
89. Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y, Wong DT. Cell cycle dysregulation in oral cancer, *Crit. Rev. Oral Bio.* 2002;13:51-6.
90. Münger K. The role of human papillomaviruses in human cancers, *Frontiers in Biosciences* 2002;7: d641-9.
91. Hasskarl J, Münger K. Id Proteins - Tumor Markers or Oncogenes, *Cancer Biology & Therapy* 2002;1:91-6.
92. Münger K. Disruption of Oncogene-tumor suppressor networks during human carcinogenesis, *Cancer Investigation* 2002;20:71-81.
93. Münger K. Papillomaviruses In "Encyclopedia of Cancer", Second Edition (JR Bertino, ed) Academic Press, San Diego 2002, vol 3:393-401.
94. Duensing S, Münger, K. Human papillomaviruses and centrosome duplication errors: Modeling the origins of genomic instability, *Oncogene* 2002;21:6241-8
95. Piboonniyom S, Duensing S, Swilling NW, Hasskarl J, Hinds PW, Münger K. Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability, *Cancer Res.* 2003;63:476-83.
96. Genther SM, Sterling S, Duensing M, Münger K, Sattler C, Lambert PF. A quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle, *J. Virol.* 2003;77:2832-42.
97. Basile JR, Eichten A, Zacny V, Münger K. NF- $\kappa$ B mediated induction of p21<sup>Cip1/Waf1</sup> by tumor necrosis factor  $\alpha$  induces growth arrest and cytoprotection in normal human keratinocytes, *Mol Cancer Res.* 2003;1:262-70.
98. Syken J, Macian F, Agarwal S, Rao A, Münger K. TID1, a mammalian homolog of the *Drosophila* tumor suppressor lethal(2) tumorous imaginal discs regulates activation-induced cell death in Th2 cells, *Oncogene* 2003;22:4636-41.
99. Riley R, Duensing S, Brake T, Münger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis, *Cancer Res.* 2003;63:4862-71.

100. Duensing S, Lee BH, Dal Cin P, Münger K. Excessive centrosome abnormalities without ongoing chromosomal instability in a malignant lymphoma, *Mol. Cancer* 2003;2:30-6.
101. Kleine-Lowinsky K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile JR, Münger K, Daly CM, Rollins BJ. Selective suppression of monocyte chemoattractant protein-1 (MCP-1) expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells, *Int. J. Cancer* 2003;107:407-15.
102. Balsitis SJ, Sage J, Duensing S, Münger K, Jacks T, Lambert PF. Recapitulation of the effects of HPV-16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo, *Mol. Cell Biol.* 2003;23: 9094-103.
103. Duensing S, Münger K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members, *J. Virol.* 2003;77:12331-35
104. Münger K. Clefs, grooves and (small) pockets: The structure of the retinoblastoma tumor suppressor to its cellular target E2F unveiled. *Proc. Natl. Acad. Sci USA* 2003;100:2165-7.
105. Duensing S, Münger, K. Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins: In *Progress in Cell Cycle Research vol 5 "Cell Cycle Regulators as Therapeutic Targets"* 2003, pp 383-91.
106. Münger K. Oncoproteines virales: In "Papillomavirus humains: biologie et pathologie tumorale" (F Aubin, JL Pretet, C Mougin eds) Editions Tec & Doc Paris/Editions Médicales Internationales Cachan, 2003 pp57-76.
107. Duensing S, Münger K. Centrosomes, genomic instability, and cervical carcinogenesis, *Critical Reviews in Eukaryotic Gene Expression* 2003;13:9-23
108. Eichten A, Rud DS, Grace M, Piboonniyom S, Zachy V, Münger K. Molecular pathways executing the "trophic sentinel" response in HPV-16 E7 expressing normal human diploid fibroblasts upon growth factor deprivation, *Virology* 2004;319: 81-93.
109. Hasskarl J, Duensing S, Manuel E, Münger K. The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers, *Oncogene* 2004;23:1930-8.
110. Edwards KM, Münger K. Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli, *Oncogene* 2004;23:8419-31.
111. Duensing S, Duensing A, Lee DC, Edwards KM, Piboonniyom S, Manuel E, Skaltsounis L, Meijer L, Münger K: The cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies, *Oncogene* 2004;23:8206-15.

112. Tarunina M, Alger L, Chu G, Münger K, Gudkov A, Jat P: A functional genetic screen for genes involved in senescence: Role of Tid1, a homologue of the *Drosophila* tumor suppressor *l(2)tid*, in senescence and cell survival, *Mol Cell Biol* 2004;24:10792-801. PMCID: PMC533960
113. Badizadegan K, Backman V, Boone CW, Crum CP, Dasari RR, Georgakoudi I, Keefe K, Münger K, Shapshay SM, Sheets EE, Feld MS. Spectroscopic diagnosis and imaging of invisible pre-cancer. *Faraday Discuss*, 2004;126: 265
114. Duensing S, Münger K. Mechanisms of genomic instability in human cancer – insights from studies with human papillomavirus oncoproteins, *Int. J. Cancer* 2004;109:157-62.
115. Edwards KM, Münger: Make WARTS not cancer, *Oncogene* 2004;23:5263-5.
116. Münger K, Duensing S. Human papillomavirus infection and centrosome anomalies in cervical cancer: In "Centrosomes in development and disease" (E Nigg Ed) Wiley-VCH Weinheim, Germany, 2004 pp 353-70.
117. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh KW: Mechanisms of Human Papillomavirus-induced Oncogenesis. *J. Virol* 2004;78:11451-6. PMCID: PMC523272
118. Hasskarl J, Velupillai P, Piboonniyom S, Grace M, Münger K: Long-term maintenance of human keratinocytes in vitro, *J. Invest. Dermatol* 2005;124:475-8.
119. DeMasi J, Huh K-W, Nakatani Y, Münger K, Howley PM: Bovine papillomavirus E7 transformation correlates with cellular p600 protein binding, *Proc. Natl. Acad. Sci. USA* 2005;102:11486-91. PMCID: PMC1182553
120. Huh K-W, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Münger K: Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600, *Proc. Natl. Acad. Sci. USA* 2005;102:11492-7. PMCID: PMC1182135
121. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Münger K, Wells SI: The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk HPV E7, *J. Virol.* 2005;79:14309-17. PMCID: PMC1280217
122. Georgakoudi I, Levitt J, Baldwin A, Papadakis A, Münger K. Intrinsic fluorescence changes associated with apoptosis of human epithelial keratinocytes. *Gynecol Oncol* 2005;99:S54-7
123. Münger K, Hayakawa H, Nguyen CL, Melquiot NV, Duensing A, Duensing S. Viral carcinogenesis and genomic instability: In "Cancer, Cell Structures, Carcinogens and Genomic Instability" EXS volume 96, Birkhauser Boston, 2005 pp 179-99

124. Hasskarl J, Velupillai P, Münger K: Increased in vitro life span of primary human keratinocytes correlates with decreased migration, *J. Invest. Dermatol* 2006;126:1179-81.
125. Baldwin A, Huh KW, Münger K: The HPV E7 Oncoprotein Dysregulates Steroid Receptor Coactivator-1 Localization and Function, *J. Virol.* 2006;80:6669-77. PMCID: PMC1488981
126. Levitt J, Baldwin A, Papadakis A, Münger K, Georgakoudi I: Intrinsic fluorescence changes associated with apoptosis of primary human epithelial cells, *J. Biomed. Optics* 2006;11:064012
127. Münger K: American Idol and NIH Grant Review--Redux. *Cell* 2006;127:661-2.
128. Nakatani Y, Münger K: p600, a novel cellular target of viral transforming proteins to evade apoptosis in neoplastic growth. *Jikken Igaku* 2006; 24:2943-6 (in Japanese)
129. Miao H, Tallarico JA, Hayakawa H, Münger K, Duffner J, Koehler AN, Schreiber SL, Lewis TA: Ring-opening and ring-closing reactions of a shikimic acid-derived substrate leading to diverse small molecules, *J. Comb. Chem* 2007;9:245-53
130. Münger K, Howley PM, DiMaio D: Human Papillomavirus E6 and E7 oncogenes: In "The Papillomaviruses" (R Garcea, D DiMaio Eds) Springer New York NY, 2007 pp195-251
131. Nguyen CL, Hayakawa H, Münger K: Activities of human papillomavirus oncoproteins that contribute to genomic instability and carcinogenic progression; In "Human Papillomavirus Gene Regulation and Transformation (B Norrild Ed) Transworld Research Network, Trivandrum, India, 2007 pp139-164.
132. Huh KW, Zhou X, Hayakawa H, Cho J-Y, Libermann TA, Jin J, Harper JW, Munger K: The human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase, which contributes to degradation of the pRB tumor suppressor, *J. Virol.* 2007;81:9737-47. PMCID: PMC2045412
133. Mujat C, Greiner C, Baldwin A, Levitt JM, Tian F, Stucenski LA, Hunter M, Kim YL, Backman V, Feld M, Munger K, Georgakoudi I: Endogenous optical biomarkers of normal and human papillomavirus immortalized epithelial cells, *Int. J. Cancer* 2007;122:363-71.
134. Nguyen CL, Eichwald C, Nibert ML, Münger K: The human papillomavirus Type 16 E7 Oncoprotein Associates with the Centrosomal Component  $\gamma$ -Tubulin, *J Virol* 2007; 81:13533-44. PMCID: PMC2168839
135. Levitt JM, Hunter M, Mujat C, McLaughlin-Drubin M, Münger K, Georgakoudi I: Extraction of cellular organization features from intrinsic fluorescence images for disease diagnosis, *Opt Lett* 2007; 32:3305-7.
136. McLaughlin-Drubin M, Münger K: Viruses Associated with Human Cancer. *Biochim Biophys Acta* 2008; 1782:127-50. PMCID: PMC2267909



137. Mangold U, Hayakawa H, Coughlin M, Munger K, Zetter BR: Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification, *Oncogene* 2008; 27:604-13.
138. Hasskarl J, Mern DS, Munger K: Interference of the dominant negative helix-loop-helix protein ID1 with the proteasomal subunit S5A causes centrosomal abnormalities, *Oncogene* 2008, 27:1657-64.
139. McLaughlin-Drubin M, Munger K: The human papillomavirus type 8 E2 gene encodes a transforming activity that is sufficient for skin tumor formation in transgenic mice. *J. Invest Dermatol* 2008; 128:2142-4
140. McLaughlin-Drubin M, Huh KW, Munger K: The Human Papillomavirus Type 16 E7 Oncoprotein Associates with E2F6, *J Virol* 2008; 82:8695-705. PMCID: PMC2519642
141. Nguyen CL, Munger, K: Direct association of the HPV16 E7 oncoprotein with cdk2/cyclin A and cdk2 cyclin E complexes, *Virology* 2008; 308:21-5. PMCID: PMC2574417
142. Grueneberg DA, Degot S, Pearlberg J, Li W, Davies JE, Baldwin A, Endege W, Doench J, Sawyer J, Hu Y, Boyce F, Xian J, Munger K, Harlow E: Kinase Requirements in Human Cells: I. Comparing Kinase Requirements Across Various Cell Types. *Proc Natl Acad Sci USA* 2008;105:16472-7
143. Baldwin A, Li W, Grace M, Pearlberg J, Harlow E, Munger K, Grueneberg DA: Kinase Requirements in Human Cells: II. Genetic Interaction Screens Identify Kinase Requirements Following HPV16 E7 Expression in Cancer Cells. *Proc Natl Acad Sci USA* 2008;105:16478-83 PMCID: PMC2575445
144. Nguyen CL, McLaughlin-Drubin ME, Munger K: Delocalization of the Microtubule Motor Dynein from Mitotic Spindles by the Human Papillomavirus E7 Oncoprotein is Not Sufficient for Induction of Multipolar Mitoses. *Cancer Res* 2008;68:8715-22. PMCID: PMC2597155
145. Mok SC, Wong K-k, Lu K, Munger K Nagymanyoki Z: Molecular Basis of Gynecologic Diseases. In: "Molecular Pathology-The Molecular Basis of Human Disease" (WB Coleman and GJ Tsongalis, eds) Elsevier-Academic Press, San Diego, 2009, pp 465-88.
146. McLaughlin-Drubin ME, Munger K: The Human Papillomavirus E7 Oncoprotein. *Virology* 2009;384:335-44. PMCID: PMC2661820
147. Zhou X, Munger K: Expression of the Human Papillomavirus type 16 E7 oncoprotein induces an autophagy-related process and sensitizes normal human keratinocytes to cell death in response to growth factor deprivation. *Virology* 2009;385:102-7. PMCID: PMC2673705

148. Nguyen CL, Munger, K: The human papillomavirus E7 protein deregulates mitosis via an association with the Nuclear Mitotic Apparatus Protein-1 (NuMA), *J Virol* 2009;83:1700-7. PMCID: PMC2643759
149. Zhou X, Spangle JM, Münger K: Expression of a viral oncoprotein in normal human epithelial cells triggers an autophagy related process – is autophagy an "Achilles' heel" of human cancers? *Autophagy* 2009; 5:578-9.
150. Hellner K, Mar JC, Fang F, Quackenbush J, Münger K: HPV16 E7 oncogene expression in normal human epithelial cells causes molecular changes indicative of an epithelial to mesenchymal transition, *Virology* 2009; 391:57-63. PMCID: PMC2728214
151. McLaughlin-Drubin M, Münger, K: Oncogenic Activities of Human Papillomaviruses. *Virus Res* 2009; 143:195-208. PMCID: PMC2730997
152. Korzeniewski N, Zheng L, Cuevas R, Parry J, Chatterjee P, Anderton B, Duensing A, Münger K, Duensing S: Cullin 1 functions as a centrosomal suppressor of centriole multiplication by regulating Polo-like kinase 4 protein levels. *Cancer Res* 2009; 69:6668-75. PMCID: PMC2727667
153. Kamil JP, Hume AJ, Jurak I, Münger K, Kalejta, RF, Coen DM: Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase. *Proc Natl Acad Sci USA* 2009; 106:16823-8. PMCID: PMC2757844
154. Baldwin A, Münger K: Molecular Events Associated with Human Papillomavirus-Induced Human Cancers. In: "Viral Oncology: Basic Science and Clinical Applications" (K Khalili and KT Jeang eds) Wiley-Blackwell, Hoboken NJ, 2010, pp 23-55
155. Nguyen CL, McLaughlin-Drubin ME, Münger K: Human Papillomaviruses and Associated Malignancies. In: "Human Oncogenic Viruses" (B Yen and J Ou, eds) World Scientific Press, Singapore, 2010, pp 137-207
156. Lowy DR, Münger K: Prognostic implications of HPV in oropharyngeal carcinoma, *New England J Med* 2010; 363: 82-4
157. Baldwin A, Grueneberg DA, Hellner K, Sawyer J, Grace W, Li W, Harlow E, Munger K: Kinase Requirements in Human Cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3, *Proc Natl Acad Sci USA* 2010; 107: 12463-8. PMCID: PMC2906576
158. Spangle JM, Münger K: The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis, *J Virol* 2010; 84: 9398-407. PMCID: PMC2937655
159. Zhou X, Münger K: Cld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis. *Cancer Res*, 2010; 70: 9434-43. PMCID: PMC2982930

160. Duensing S, Darr S, Cuevas R, Melquiot N, Brickner AG, Duensing A, Munger K: Tripeptidyl peptidase II is required for c-MYC-induced centriole overduplication and a novel therapeutic target in c-MYC-associated neoplasms. *Genes & Cancer* 2010; 1:883-892. PMID: PMC3092256
161. McLaughlin-Drubin ME, Crum C, Munger K: The Human Papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming, *Proc Natl Acad Sci U S A.* 2011; 108: 2130-5. PMID: PMC3033314
162. Hellner K, Munger K: Human papillomaviruses as therapeutic targets in human cancer, *J. Clin Oncol* 2011; 29: 1785-94.
163. Levitt JM, McLaughlin-Drubin ME, Munger K, Georgakoudi I: Automated Biochemical, Morphological, and Organizational Assessment of Precancerous Changes from Endogenous Two-Photon Fluorescence Images, *PLOS ONE* 2011, 6: e24765. PMID: PMC3170385
164. Munger K, Duensing S: Induction of genomic instability by human papillomavirus oncoproteins. In "Small DNA Tumour Viruses" (K Gaston ed) Caister Academic Press, Norfolk UK, 2012, pp 239-54.
165. White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Munger K, Harper JW, Howley PM: Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses, *Proc Natl Acad Sci U S A.* 2012, 109(5): E260-7. PMID: PMC3277141
166. Spangle JM, Gosh-Choudhury N, Munger K: Activation of cap dependent translation by mucosal Human Papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif, *J. Virol* 2012, 86: 7466-72. PMID: PMC3416298
167. Gulbahce N, Yan H, Dricot A, Padi M, Byrdsong D, Franchi R, Lee D-S, Rozenblatt-Rosen O, Mar JC, Calderwood MA, Baldwin A, Zhao B, Santhanam B, Braun P, Huh K-W, Hellner K, Grace M, Chen A, Rubio R, Marto JA, Christakis NA, Kieff E, Roth FP, Roeklein-Canfield J, DeCaprio JA, Cusick ME, Quackenbush J, Hill DE, Munger K, Vidal M, Barabasi AL: Viral perturbations of host networks reflect disease etiology, *PLoS Comput Biol* 2012; 8: e1002531. PMID: PMC3386155
168. Klionsky DJ, (...774 authors...), Munger K, (...493 authors...): Guidelines for the use and interpretation of assays for monitoring autophagy, *Autophagy* 2012, 8: 445-544. PMID: PMC3404883
169. McLaughlin-Drubin ME, Meyers J, Munger K: Cancer-associated human papillomaviruses, *Curr Op Virol* 2012; 2:459-66. PMID: PMC3422426
170. Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, Munger K, Feldman S, McKeon FD, Xian W, PhD, Crum CP: The squamo-columnar junction and the cell of origin for cervical cancer, *Proc Natl Acad Sci USA,* 2012; 109:10516-21. PMID: PMC3387104

171. Yu Y, Munger K: Human Papillomavirus Type 16 E7 oncoprotein engages but does not abrogate the mitotic spindle assembly checkpoint, *Virology* 2012; 432:120-6. PMCID: PMC3402702
172. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, Pevzner S, Abderazzaq F, Byrdsong D, Carvunis A-R, Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg BK, Gulbahce N, Hao T, Holthaus A, James R, Korkhin A, Litovchick L, Mar JC, Pak TR, Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT, Roecklein-Canfield J, Johannsen E, Barabási A-L, Beroukhim R, Kieff E, Cusick ME, Hill DE, Münger K, Marto JA, Quackenbush J, Roth FP, DeCaprio JA, Vidal M: Interpreting cancer genomes using systematic host perturbations by tumour virus proteins, *Nature* 2012; 487:491-5. PMCID: PMC3408847
173. Mack HID, Munger K: Modulation of autophagy-like processes by tumor viruses, *Cells* 2012, 1, 204-47. PMCID: PMC3901111
174. Meyers JM, Spangle JM, Munger K: The HPV8 E6 protein interferes with NOTCH activation during keratinocyte differentiation, *J Virol* 2013; 87:4762-7. PMCID: PMC3624394
175. Spangle JM, Munger K: The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species, *PLOS Pathogens* 2013; 9:e1003237. PMCID: PMC3597533
176. McLaughlin-Drubin ME, Munger K: Biochemical and functional interactions of human papillomavirus proteins with polycomb group proteins, *Viruses* 2013; 5: 1231-1249. PMCID: PMC3712305
177. Mack HID, Munger K: The LKB1 tumor suppressor differentially affects anchorage independent growth of HPV positive cervical cancer cell lines, *Virology* 2013; 446:9-16. PMCID: PMC3843939
178. Roman A, Munger K: The papillomavirus E7 proteins, *Virology* 2013; 445: 138-68. PMCID: PMC3783579
179. Yu Y, Munger K: Human Papillomavirus Type 16 E7 oncoprotein inhibits the anaphase promoting complex/cyclosome activity by dysregulating EMI1 expression in mitosis, *Virology* 2013; 446:251-259. PMCID: PMC3799973
180. McLaughlin-Drubin ME, Park D, Munger K: Tumor suppressor p16<sup>INK4A</sup> is necessary for survival of cervical carcinoma cell lines, *Proc. Natl. Acad. Sci USA* 2013; 110:16175-80. PMCID: PMC3791710
181. Munger K, Gwin TK, McLaughlin-Drubin M: p16 in HPV-associated cancers, *Oncotargets* 2013; 4:1864-5. PMCID: PMC3875753
182. Munger K: Are Selective Estrogen Receptor Modulators (SERMs) a therapeutic option for HPV-associated cervical lesions and cancers? *Am. J. Path.* 2014; 184:358-61

183. Quesnelle K, Grandis J, Munger K, Posner MR: Head and Neck Cancer. In "Molecular Oncology: Causes of Cancer and Targets for Treatment" (E. Gelman, C Sawyers and F. Rauscher III, eds) Cambridge University Press, Cambridge UK, 2014, pp 497-505.
184. Mesri EA, Feitelson M, Munger K: Human Viral Oncogenesis: A Cancer Hallmark Analysis, *Cell Host and Microbes* 2014; 15:266-82. PMID: PMC3992243
185. Spangle JM, Chen AA, Munger K: Human Papillomavirus: Pathogenesis and Host Immune Response. In "Viruses and Human Cancer" (D Hudnall, Ed), Springer, New York, NY, pp 167-97.
186. McLaughlin-Drubin ME, Munger K: Papillomaviruses. In: "Reference Module in Biomedical Sciences", Elsevier, Oxford, UK, 2014; doi:10.1016/B978-0-12-801238-3.00007-6 (<http://www.sciencedirect.com/science/article/pii/B9780128012383000076>)
187. Varone A, Xylas JF, Quinn KP, Pouli D, Sridharan G, McLaughlin-Drubin ME, Alonzo C, Lee K, Munger K, Georgakoudi I: Endogenous two-photon fluorescence imaging elucidates metabolic changes related to enhanced glycolysis and glutamine consumption in pre-cancerous epithelial tissues, *Cancer Research*, 2014; 74:3067-75 PMID: 24686167; PMID: PMC4837452
188. Meyers JM, Munger K: The viral etiology of skin cancer, *J Invest Dermatol*, 2014, 134:E29-32
189. Xylas JF, Varone A, Quinn KP, Pouli D, McLaughlin-Drubin ME, Thieu H-T, Garcia-Moliner ML, House M, Hunter M, Munger K, Georgakoudi I: Non-invasive assessment of mitochondrial organization in three-dimensional tissues reveals changes associated with cancer development, *Int J Cancer*, 2015; 136:322-32. PMID: 24862444
190. Munger K, Jones DL: Human papillomavirus carcinogenesis - An identity crisis in the retinoblastoma tumor suppressor pathway, *J Virol*, 2015, 89:4708-11. PMID: 25673729; PMID: PMC4403492
191. Munger K: Viruses and cancer – an accidental journey, *PLOS Pathogens*, 2016; 12: e1005573. PMID: 27606603; PMID: PMC5015859
192. White EA, Munger K, Howley PM: High-risk human papillomavirus E7 proteins target PTPN14 for degradation, *mBio* 2016; 7: e01530-16. PMID: 27651363; PMID: PMC5030362
193. Grace M, Munger K: Proteomic analysis of the gamma human papillomavirus type 197 E6 and E7 associated cellular proteins, *Virology* 2017; 500: 71-81. PMID: 27771561; PMID: PMC5127743
194. Meyers JM, Uberoi A, Grace M, Lambert PF, Munger K: Cutaneous HPV8 and MmuPV1 E6 proteins target the NOTCH and TGF- $\beta$  tumor suppressors to inhibit differentiation and sustain keratinocyte proliferation, *PLOS Pathogens* 2017; 13:e1006171. PMID: 28107544; PMID: PMC5287491
195. Harden ME, Prasad N, Griffith A, Munger K: Modulation of microRNA-mRNA Target Pairs by Human Papillomavirus 16 Oncoproteins, *mBio* 2017; 8:e02170-16. PMID: 28049151; PMID: PMC5210503

196. Harden ME, Munger K: Perturbation of DROSHA and DICER expression by Human Papillomavirus 16 Oncoproteins, *Virology* 2017; 507:192-8. PMID: 28448850
197. Harden ME, Munger K: Human Papillomavirus 16 E6 and E7 oncoprotein expression alters microRNA expression in extracellular vesicles, *Virology* 2017; 508:63-9. PMID: 28500882
198. Harden ME, Munger K: Human papillomaviruses molecular biology, *Mut Res* 2017;772:3-12.
199. Miller AK, Munger K, Adler FR: A mathematical model of cell cycle dysregulation due to human papillomavirus infection, *Bull Math Biol* 2017; in press
200. Soto DR, Barton C, Munger, K, McLaughlin-Drubin ME: KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21<sup>CIP1</sup> suppression of replication stress, in revision

#### Thesis:

Münger K. Chemical and molecular biological studies on copper metallothioneins from fungi, University of Zürich, Zürich, Switzerland (1986).

#### Nonprint Material:

Halpern AL, Münger K. HPV-16 E7: Correspondence between primary structure and biological properties. HPV Sequence Database, Los Alamos National Laboratory, 1995, pp III-58-III-73 (<http://hvp-web.lanl.gov/HPVonLine.html#comp95>).

#### Patents:

"Method and kit for evaluating transformed cells." US Patent 5736318; Issue date 04/07/1998

"Methods and reagents to regulate apoptosis" US Patent.6825005; Issue date 11/30/2004

"Compositions and Methods for Inhibiting Cell Growth." PCT/US2010/037280, Filing Date 6/3/10.

"H3K27me3 and Cancer." PCT/US10/41962; Filing Date 7/15/10.



SETTI D. WARREN  
MAYOR

City of Newton, Massachusetts  
Office of the Mayor

#243-17

Telephone  
(617) 796-1100

Facsimile  
(617) 796-1113

TDD/TTY  
(617) 796-1089

E-mail  
swarren@newtonma.gov


Honorable City Council  
Newton City Hall  
1000 Commonwealth Avenue  
Newton, MA 02459

Ladies and Gentlemen:

I am pleased to appoint Julie A. Norstrand of 44 Stearns Street, Newton as a Commissioner of the Newton Council on Aging. Her term of office shall expire September 30, 2020 and her appointment is subject to your confirmation.

Thank you for your attention to this matter.

Very truly yours,

  
Setti D. Warren  
Mayor

RECEIVED  
Newton City Clerk  
2017 AUG -2 PM 2:23  
David A. Olson, CMC  
Newton, MA 02459

1000 Commonwealth Avenue Newton, Massachusetts 02459

[www.newtonma.gov](http://www.newtonma.gov)



DEDICATED TO COMMUNITY EXCELLENCE

**Julie A. Norstrand, MS, MSW, PhD.**  
44 Stearns St., Newton, MA 02459

## EDUCATION

**Boston College**, Boston, MA

MSW/PhD Candidate in Social Work (MSW, May 2009) (PhD, May, 2014)

Dissertation: The association between social capital and health among community dwelling older adults  
(Committee: Lubben, J. (Chair); Berkman, B; Glicksman, A; Mahoney, K; Moorman, S.)

**M.C.P. Hahnemann**, Philadelphia, PA

Master of Science in Clinical Psychology, May 2002

Thesis: Depressive symptomatology in medical rehabilitation patients: Patient's or caregiver's social problem-solving abilities as predictors

**University of Newcastle upon Tyne**, Newcastle upon Tyne, England

Bachelor of Science in Psychology, June 1995

## AWARDS

- Hartford Change AGENTS Policy Institute (2014)
- John A. Hartford Geriatric Social Work Dissertation Fellowship (2011-2013)
- Ruth Landes Memorial Research Fund; declined in lieu of receipt of Hartford Fellowship (2011)
- Boston College University Institute on Aging Dissertation Award (2011)
- John A. Hartford Geriatric Social Work Pre-dissertation Award (2007-2009)
- Boston College Graduate School of Social Work Doctoral Fellowship (2005-2008)

## RESEARCH INTERESTS

- Social capital and health among older adults
- Global aging demography
- Aging workforce
- Civic engagement among older adults

## PEER-REVIEWED PUBLICATIONS:

Xu, Q., **Norstrand, J.A.** & Du, Y. (2016). Effects of living alone on social capital and health among older adults in China. *Int J Aging Hum Dev*. Advance online publication. doi: 10.1177/0091415015624419.

**Norstrand, J.A.** & Glicksman, A. (2015). Influence of living arrangements of community dwelling older adults on the association between social capital and health. In F. Nyqvist & A.K. Forsman (Eds.) *Social capital and health among older people: the meaning of community and context* (pp. 89-109) NY: Springer.

**Norstrand, J.A.** & Chan, K. (2014). The relationship between health and community across aging cohorts. *J Aging Research*, Article ID 626097, 10 pages.

**Norstrand, J.A.**, Glickman, A., Lubben, J., Kleban, M. (2012). The role of the social environment on physical and mental health of older adults. *J Housing for Elderly*, 26(1-3), 290-307.

Xu, Q. & **Norstrand, J.A.** (2012). Gendered Social Capital and Health Outcomes among Older Adults in China. In S. Chen & J.L. Powell (Eds.), *Aging in China: Implications to Social Policy of a Changing Economic State* (pp.147-168) NY: Springer.



- Norstrand, J.A. & Xu, Q. (2012) Social capital and health among older adults in China: The Urban-rural dimension. *The Gerontologist*, 52(3), 325-334.
- Lombe, M., Ochumbo, A.J., Norstrand, J.A. (2008). Attainment of Basic Needs as a Predictor of Civic Engagement in Sub-Saharan Africa: Some Implications. *Journal of Comparative Social Welfare*, 24(2), 103-117.
- Shen, C., Smyer, M.A., Mahoney, K.J., Simon-Rusinowitz, L., Shinogle, J., Norstrand, J.A., Schauer, C., del Vecchio, P. (2008). Consumer direction, personal care, and well-being for Medicaid beneficiaries with mental health diagnoses: Lessons from the New Jersey Cash & Counseling Program. *Psychiatric Services*, 59(11), 1299-1307.
- Kohler, C., Norstrand, J.A., Baltuch G., O'Connor MJ., Gur, R.E., French J.A., Sperling M.R. (1999). Depression in temporal lobe epilepsy before epilepsy surgery. *Epilepsia*, 40(3), 336-40.
- Kohler, CG., O'Connor, MJ., Baltuch, G., Norstrand J.A., French, J. A., Sperling, MR. (1998). Mood disorders at early follow-up after temporal lobectomy. *Epilepsia*, 39 Supplement 6, 241.
- Coleman AR., Norstrand J.A. Moberg PJ. Kohler CG. Gur RC. Gur RE. (1998). MMPI-2 characteristics of adults diagnosed with attention deficit disorder. *International Journal of Neuroscience*, 96(3-4), 161-75.
- Kohler, C., Liporace, JD., Sirven, JJ., Crino, P., King, D., O'Connor, MJ., Baltuch, G., Shanker, V., Norstrand, J.A., French, JA., Sperling, MR. (1997). Presurgical depression in temporal lobe epilepsy. *Epilepsia*, 38 Supplement 8, 153-154.
- Kohler, C., Norstrand, J.A., Shanker, V., Gur, RE., O'Connor, MJ., Sperling, MR. (1996). Depression in right and left temporal lobe epilepsy patients. *Epilepsia*, 37 Supplement 5:17.

## OTHER PUBLICATIONS

- Norstrand, J.A. (2010). Denmark: Public Policy. The Sloan Center on Aging & Work, Boston College, Chestnut Hill, MA.
- Norstrand, J.A. (2009). Mind the Gap: Denmark. The Sloan Center on Aging & Work, Boston College, Chestnut Hill, MA.
- Norstrand, J.A. (2009). Denmark: Statistical Profile. The Sloan Center on Aging & Work, Boston College, Chestnut Hill, MA.
- Norstrand, J.A., Mahoney, K.J., Loughlin, D.M., Simon-Rusinowitz, L. (2009). What impact does the ability to purchase goods and services have on participants in Cash & Counseling Programs? National Resource Center for Participant-Directed Services.
- Glicksman, Allen, Norstrand, J.A. (2004). The Socio-Economic and Health Characteristics of Philadelphia's Elderly Population. Philadelphia Corporation for Aging.

## PRESENTATIONS

- Norstrand, J.A., Moon, H. & Tran, T. (Nov. 2013) *Theoretical and practical considerations when conducting cross-national aging research*. Annual Scientific Meeting of the Gerontological Society of America 66<sup>th</sup> Conference, New Orleans, LA.
- Norstrand, J.A., Lubben, J., Berkman, B., Glicksman, A., Mahoney, K., Moorman, S. (Nov. 2012) *Conceptualization of social capital from social work perspective: Building on Environmental Gerontology*. Annual Scientific Meeting of the Gerontological Society of America 65<sup>th</sup> Conference, San Diego, CA.

- Norstrand, J.A.**, Moorman, S. (Nov. 2010). *The relationship between social capital and health: The role of social inequality*. Annual Scientific Meeting of the Gerontological Society of America 63<sup>rd</sup> Conference, New Orleans, LA.
- Norstrand, J.A.**, Glicksman, A., Lubben, J., Kleban, M. (Nov. 2009). *Social capital among older adults: Implications for physical and mental health*. Annual Scientific Meeting of the Gerontological Society of America 62<sup>nd</sup> Conference, Atlanta, GA.
- Norstrand, J.A.**, Glicksman, A., Kleban, M. (Nov. 2009). *How does the social environment impact trust in the health care system among older adults?* Annual Scientific Meeting of the Gerontological Society of America (GSA) 62<sup>nd</sup> Conference, Atlanta, GA.
- Norstrand, J.A.**, Glickman, A., Kleban, M. (Nov. 2008). *What is the relationship between social capital and health of an elderly sample living in Philadelphia?* Annual Scientific Meeting of the Gerontological Society of America 61<sup>st</sup> Conference, National Harbor, MD.
- Norstrand, J.A.**, Mahoney, K.J. (Mar., 2007) *Best practices for engaging students in academic research settings*. Research Retreat, Boston College, MA.
- Norstrand, J.A.**, Glickman, A., Kleban, M. (Nov. 2006). *Impact of social capital on health in three consecutive aging cohorts*. Annual Scientific Meeting of the Gerontological Society of America 59<sup>th</sup> Conference, Orlando, FL.
- Norstrand, J.A.**, Glicksman, A. (Nov. 2005). *Social capital amongst the elderly in Philadelphia*. Annual Scientific Meeting of the Gerontological Society of America 58<sup>th</sup> Conference, Washington, D.C.
- Glicksman, A, **Norstrand, J.A.**, Kleban, M, Klein, J. (Mar 2005). *Improving the Physical Health of Caregivers to the Elderly*. Annual Joint Meeting of the American Society on Aging/National Council on Aging, Philadelphia, PA.
- Glicksman, A., **Norstrand, J.A.**, Kleban, M., Klein, J. (Nov. 2004). *The Impact of a Caregiver Health Intervention on Physical Health Status*. Annual Scientific Meeting of the Gerontological Society of America 57<sup>th</sup> Conference, Washington, D.C.
- Norstrand, J.A.**, Glicksman, A, Kleban, M., Klein, J. (Nov. 2004). *Impact of Intervention by Nurse on the Mental Health of Caregivers*. Annual Scientific Meeting of the Gerontological Society of America 57<sup>th</sup> Conference, Washington, D.C.
- Norstrand, J.A.** (Oct. 2004). *Social Capital Amongst Older Philadelphians: Implications for Emergency Preparedness*. Conference on Emergency Preparedness for Older Persons: Paris and New York City, International Longevity Center, New York, NY.
- Glicksman, A., **Norstrand, J.** (Oct. 2004). *Preparing for the Future: Current Status and Projected Changes for Philadelphia's Elderly Population: 2005 – 2015*. Institute on Aging Pew Foundation Center at University of Pennsylvania, Philadelphia, PA.
- Norstrand, J.** (Apr. 2004). *What Are the Predictors of Depression in the Context of an Urban Environment?* Hartford Center on Geriatric Nursing Excellence, University of Pennsylvania, Philadelphia, PA.
- Glicksman A., **Norstrand, J.** (Sept. 2004). *Older Philadelphians: Current Status and Future Trends*. Population Studies Center of the University of Pennsylvania, Philadelphia, PA.

## SESSIONS CHAIRED

- Co-chair. (Nov. 2013). Aging in multiple environmental settings: What factors contribute to optimal aging? Informal Interest Group on Environmental Gerontology. Annual Scientific Meeting of the Gerontological Society of America 66<sup>th</sup> Conference, New Orleans, IL.
- Chair. (Nov. 2012). Multidisciplinary examination of social capital to further advance Environmental Gerontology. Annual Scientific Meeting of the Gerontological Society of America 65<sup>th</sup> Conference, San Diego, CA.
- Chair. (Nov. 2011). Advances in the conceptualization of social capital and understanding its relationship to health outcomes among older adults. Annual Scientific Meeting of the Gerontological Society of America 64<sup>th</sup> Conference, Boston, MA.
- Co-chair. (Nov. 2011). Advances in the conceptualization and measurement of neighborhoods. Informal Interest Group on Urban and Neighborhood Aging. Annual Scientific Meeting of the Gerontological Society of America 64<sup>th</sup> Conference, Boston, MA.

## POSTER PRESENTATIONS

- Xu., Q., Norstrand, J.A. (2011). *Gendered Relationships between Social Capital and Health among Older Adults in China.* Poster presentation at the Annual Scientific Meeting of the Gerontological Society of America 63<sup>rd</sup> conference, Boston, MA.
- Norstrand, J.A., Xu, Q. (2010). *Social capital and health among older adults in China: The Urban-rural dimension.* Poster presentation at the Annual Scientific Meeting of the Gerontological Society of America 63<sup>rd</sup> conference, New Orleans, LA.
- Norstrand, J.A., Glicksman, A., Lubben, J., Kleban, M. (Jul., 2009). *The importance of the social environment to health and mental health among older adults.* 19<sup>th</sup> IAGG World Congress of Gerontology and Geriatrics, Paris, France.
- Norstrand, J.A., Mahoney, K. (Oct., 2008). *What impact does ability to purchase goods and services have on participants in Cash & Counseling programs.* 24<sup>th</sup> National Home and Community Based Services Conference, NASUA, Boston, MA.
- Glicksman, A., Norstrand, J.A. (Apr., 2005). *Demographic profile of the elderly.* M. Powell Lawton Conference on the Health of the Urban Elderly in the Next Decade, Philadelphia, PA.
- Glicksman, A., Norstrand, J.A. (May, 2004). *Socio-Economic and Health Characteristics of Philadelphia's Elderly Population.* Annual Poster Session of the Institute on Aging of the University of Pennsylvania Health System, Philadelphia, PA.

## TEACHING EXPERIENCE

- Adjunct Faculty, Fall 2015: Social work in Health Care Settings. Regis College, Weston MA
- Adjunct Faculty, Fall 2011: Diversity & Cross Cultural Issues. Boston College, Chestnut Hill, MA
- Teaching Associate, Fall 2010: Human Behavior & Social Environment. Boston College, Chestnut Hill, MA
- Guest speaker, Fall 2010: Aging & Society. Boston College, Chestnut Hill, MA

## PROFESSIONAL RESPONSIBILITIES

- Board member of Massachusetts Gerontology Association (2013-present)
- Board member (waiting for confirmation) of Council on Aging, Newton Senior Center (2015-present)
- Co-convener of GSA Special Interest Group "Environmental Gerontology." (2011-present)

## REVIEWER

- The Gerontologist
- International Journal of Aging and Human Development
- Journal of Aging Research
- Journal of Community Practice
- Population Studies

## PROFESSIONAL MEMBERSHIPS

- Gerontological Society of America (2004-present)
- Massachusetts Gerontology Association (2005-present)
- National Association of Social Work (2015-present)

## RESEARCH EXPERIENCE

### **The Sloan Center on Aging & Work at Boston College, Chestnut Hill, MA**

#### Research Assistant (June 2009 – June 2010)

- Compiled 3 reports for Country Context Studies: secondary data analysis and interpretation of employment data in Denmark

### **National Resource Center for Participant-Directed Services, Boston College, Chestnut Hill, MA**

#### Research Assistant (Sept. 2006 – May 2007)

- Secondary data analysis for SAMHSA sponsored project Learning from the Cash & Counseling demonstration and evaluation: People with mental illness self-directing care.
- Primary data collection, interpretation, and write up findings for report on how students are employed in academic research centers.
- Primary and secondary data collection, interpretation and write up of findings for report looking at C&C users to get a better understanding of impact a truly flexible spending plan has on participants' well-being.

### **Office of Healthy Aging, Department of Public Health, Boston, MA**

#### Research Assistant (Sept. 2005 – May 2006)

- Developed report on chronic disease and disability among older adults (50+) in Boston.
- Developed goals and outline for report, secondary data analyses.
- Interviewed public health program directors and older adults; interpreted and wrote-up of findings.

## PROGRAM MANAGEMENT EXPERIENCE

### **Research and Evaluation Program, Philadelphia Corporation on Aging (PCA)**

#### Research Assistant, (March 2003 to July 2005)

#### Grant related activities: Project Manager for Administration on Aging.

Title: Supporting Older African American Caregivers: Assessing Needs, Building Skills, and Maintaining Health.  
Grant No: 90CG2530. P.I.: Klein, Joan.

- Data management and general data analysis
- Semi-annual report writing and renewal application
- Analyzing and reporting on mental health outcomes
- NIMH Grants applications: assisted with: design overall research outline, literature review and write-up of sections of grant such as Aims, Significance sections and Method

#### Program evaluations:

- Designed evaluation and questionnaire, set-up focus groups, data collection and analyses using SPSS and Ethnograph; wrote-up of reports

#### First author /sole author on:

- City wide findings of Legislative survey for Communications, PCA (1/03)

- Long Term Care Survey for Philadelphia Partnership Long Term Care Coalition (9/03)
- Evaluation of the Clergy Outreach Program for Clergy Program, PCA (1/04)
- Housing survey for Housing subcommittee for Community Choice, PCA (7/04)

Co-author on:

- Case-Mix Index survey for Long Term Care, PCA (5/04)

Consulting:

Provided information on state of city's elderly and environment in which they live. This information is designed for use both within the agency and by individuals and organizations outside the agency with an interest in the lives of the city's elderly. Data obtained mostly from Census 2000, Integrated Public Use Microdata Series, and Philadelphia Health Management Corporation Data.

## **CLINICAL EXPERIENCE**

### **Philadelphia Corporation for Aging, Philadelphia, PA**

#### Training Assistant (July 2002 – February 2003)

- Mental Health and Aging Graduate group: facilitated meetings and organized outside speakers

### **Supportive Older Women's Network (SOWN), Philadelphia, PA**

#### Group Facilitator (May 2001 – May 2002)

- Set-up and facilitation of community based support groups; planning and development of session material; editing and distribution of SOWN's newsletter; public speaking at fundraising events

### **University of Hospital Pennsylvania, Philadelphia, PA**

#### Practicum Student, Dept. of Rehabilitation Medicine, (Sep. 1999 – May 2000)

- Provision of psychotherapy, primarily cognitive-behavioral, to medically ill adult rehabilitation population (including stroke, spinal cord injury, amputees, gun shot)

#### Practicum Student, Dept. of Psychiatry, Center for Cognitive Therapy, (Jan. – May 1999)

- Provided diagnostic evaluation using psychiatric scales and Structured Clinical Interview for DSM-IV for wide range of disorders (substance related, mood, anxiety, adjustment, and personality).

#### Student Research Neuropsychologist Intern, (Mental Health Clinical Research Ctr), (Sept. 1998 – Sept. 1999, September 1995 – 1998).

- Provided clinical Evaluation: assessment, scoring, interpretation, report writing, feedback (primarily cases involving memory impairment, attention deficit disorder, learning disability, psychosis, heart transplant, pain).
- Experimental battery: Administration, scoring, and interpretation of a 3-5 hour standardized and experimental neuropsychology battery, (paper & pencil, and computerized).
- Clinical evaluation: Clinical and diagnostic interview, administration, scoring and interpretation of neuropsychological measures, report writing and feedback/consultation to patients, families and referral sources. Clinical patients include schizophrenia, (inpatients and outpatients), depression, bipolar disorder, attention deficit disorder (ADD), memory impairment, back pain, heart transplant and normal control adults.
- Research Experience
- 1) Depression in right and left temporal lobe epilepsy: Collection of Event Related Potentials, administration of facial discrimination computerized task, database management and statistical analysis.
- 2) Efficacy of stimulant medication of cognitive and behavioral aspects of ADD: Administration of psychiatric scales (pre and post medication), database management and statistical analysis.
- 3) MMPI-2 profile of ADD

## **VOLUNTEER POSITIONS**

### **Global Action on Aging, NYC, NY**

#### Intern (May 2001 – Dec 2003)

- Conducted health and social policy research on aging in Denmark posted on Global Aging website; opportunity to meet diplomats, UN staff, researchers, policy experts, and citizen organizational leaders

**Philadelphia Refugee Mental Health Network, Philadelphia, PA**

Volunteer for Referral Committee (Aug 2001 – Sept 2002)

- Development of mental health referral network for refugees with mental health problems

**Delaware Valley Mental Health Aging Advocacy Committee, Philadelphia, PA**

Advocate for the Aging (April 2000 – Sept 2001)

- Professionals working in aging services focus on increasing awareness of mental health and aging issues and provide forum for discussion and exchange of information

**REFERENCES**

Allen Glicksman, Ph.D., Director of Research and Evaluation, Philadelphia Corporation for Aging, 642 North Broad Street, Philadelphia, PA 19130-3424, Tel: 215-765-9000, Fax: 215-765-9066, E-mail: [aglicksman@pcaphl.org](mailto:aglicksman@pcaphl.org)

James Lubben, Ph.D., Professor and Louise McMahon Ahearn Chair, PhD Program Director, Institute on Aging Director, Graduate School of Social Work, McGuinn Hall, Rm., 118, Boston College, Chestnut Hill, MA 02467, Tel: 617-552-1366, E-mail: [lubben@bc.edu](mailto:lubben@bc.edu)

Kevin Mahoney, Ph.D., Professor, Director of National Resource Center for Participant-Directed Services, Haley House, 314 Hammond St., Room 220, Boston College, Chestnut Hill, MA 02467, Tel: 617-552-4039, E-mail: [Kevin.mahoney@bc.edu](mailto:Kevin.mahoney@bc.edu)



SETTI D. WARREN  
MAYOR

City of Newton, Massachusetts  
Office of the Mayor

Telephone  
(617) 796-1100

Facsimile  
(617) 796-1113

TDD/TTY  
(617) 796-1089

E-mail  
swarren@newtonma.gov


Honorable City Council  
Newton City Hall  
1000 Commonwealth Avenue  
Newton, MA 02459

Ladies and Gentlemen:

I am pleased to appoint Donna Murphy of 496 Commonwealth Avenue, Newton as a Commissioner of the Newton Council on Aging. Her term of office shall expire September 30, 2020 and her appointment is subject to your confirmation.

Thank you for your attention to this matter.

Very truly yours,

  
Setti D. Warren  
Mayor

RECEIVED  
Newton City Clerk  
2017 AUG -2 PM 2:23  
David A. Olson, CMC  
Newton, MA 02459

1000 Commonwealth Avenue Newton, Massachusetts 02459

[www.newtonma.gov](http://www.newtonma.gov)



DEDICATED TO COMMUNITY EXCELLENCE

**Denna M. Murphy**  
 496 Commonwealth Avenue  
 Newton, MA 02459

---

## Overview

- ❖ Seasoned manager with extensive international, public and private sector experience
  - ❖ Demonstrated ability to introduce, manage, develop and deliver new products and services in start-ups, large public entities and corporate environments.
  - ❖ Experienced in all aspects of technology management including online and backend application development, networks and network services, telecommunications, call centers and service delivery.
- 

**Burning Glass, 2013- current**  
**Vice President, Technology**

**Boston, MA**

Manage all aspects of software development, network, and infrastructure for this growing company specializing in talent management and matching jobseekers with available jobs.

**Management Consultant, 2009 – 2012**

**Boston, MA**

Strategic management consultant providing services in the areas of:

- \* Strategic planning;
- \* Business process design;
- \* Aging workforce/aging population planning and impact analysis;
- \* Online strategy, including usability and market analysis;
- \* Online and backend application design, development and implementation;
- \* Data design and security;

**Adecco Institute, 2008**

**London, UK**

**Managing Director**

Conducted research on global workforce trends including the aging of the workforces in industrialized nations, the employability gap in India, and worker retention in China, in addition to publishing and speaking on global issues such as talent management. Managed workforce surveys, wrote opinion and white papers, presented study results throughout the US, EU and Asia, and established alliances with academic and research institutes globally to deepen insights into the relevant localities.

**Commonwealth of Massachusetts, 2004 – 2008**

**Boston, MA**

**Chief Information Officer/Chief of Staff, Department of Workforce Development,**  
**2005 – 2008**

Responsible for a 2000 person, \$2B+ government agency that provides unemployment insurance, employment services, workers compensation, and a variety of other services. Managed complex state and federal contracts and coordinated among multiple local constituencies, governmental agencies, and the state legislature to meet agency objectives. Key accomplishments include the launch of a project to replace the State's legacy unemployment insurance system, development of a system to manage the State's newly introduced comprehensive health insurance system, and introduction of direct deposit for payment of unemployment benefits.

**Chief of Staff, Division of Unemployment Assistance**

**2004 – 2005**

Established organizational goals and metrics, managed the budget, and controlled the complex



reporting requirements of this \$1B+ agency. Launched the agency's Fraud unit and introduced the discipline of business case planning to justify proposed expenditures.

### **3Com Corporation, 1999 – 2004**

**Santa Clara, CA and Singapore**

#### **Vice President, Web Enablement and Asia Pacific IT**

Managed the Singapore-based Asia Pacific IT organization with staff in six Asian countries supporting 14 regional operations. Redesigned and updated the regional network, developed security and disaster recovery plans, and deployed new software (including SAP and Web-enabled applications) while supporting the manufacturing, sales, and distribution organizations of this \$6B business. As the Vice President responsible for Web-enabling key business processes, developed a corporate IT architecture and identified and implemented global initiatives using multi-functional, worldwide task forces. Increased eCommerce revenues 300%, delivered productivity gains measured at three weeks per employee per year, and recognized cost savings exceeding \$200M/year.

### **ITT Corporation, 1987 – 1998**

Over the course of eleven years with ITT Corporation, progressed through a series of increasingly senior positions, culminating in the role of Chief Operating Officer for ITT New Media Services, a division of ITT established to focus on integrating Internet technologies into the corporation. Roles spanned three continents and six countries. At the time, ITT companies included Sheraton Hotels, Caesars Palace and Casinos, Madison Square Garden, ITT Technical Schools and ITT World Directories.

#### **Key Roles:**

Chief Operating Officer of ITT New Media Services – Manhattan, NY  
 Acting CIO of Caesars Palace and Casinos – Las Vegas, NV  
 Senior Systems Manager of Nippon Directories Development Corp – Osaka, Japan  
 Divisional Planning Manager of ITT World Directories – Brussels, Belgium  
 Senior Program Manager of ITT Publitec – Amsterdam, The Netherlands

#### **Highlights:**

Developed and launched ITT's online business. Established partnerships with emerging Internet companies and launched online reservations (Sheraton Hotels), and an online gaming initiative (Caesars Palace).

Implemented disaster recovery plans business-wide.

Built a shared services organization deploying Peoplesoft and Oracle applications for HR, Purchasing and Finance; bottom line impact > \$150M/yr.

Managed a global team of over 600 in the design, development and implementation of a national, \$100M business support system for NTT Directory Operations in Japan.

Successfully brokered an agreement between ITT, the PTT in Turkey, and third party vendors resulting in the delivery of Turkey's first nationwide directory assistance system.

Executed a technology transfer project \$1M under budget and four months ahead of plan, enabling deployment of core operating software and saving over \$30M in technology costs.

---

#### **Education**

**Boston College Graduate School of Management**

MBA International Strategic Management

May, 1987

**Harvard University**

AB Applied Mathematics/Computer Science

June, 1983

---



SETTI D. WARREN  
MAYOR

City of Newton, Massachusetts  
Office of the Mayor

#245-17

Telephone  
(617) 796-1100

Facsimile  
(617) 796-1113

TDD/TTY  
(617) 796-1089

E-mail  
swarren@newtonma.gov


Honorable City Council  
Newton City Hall  
1000 Commonwealth Avenue  
Newton, MA 02459

Ladies and Gentlemen:

I am pleased to appoint Chryse Gibson of 19 Hampden Terrace, Newton as a Commissioner of the Newton Council on Aging. Her term of office shall expire September 30, 2020 and her appointment is subject to your confirmation.

Thank you for your attention to this matter.

Very truly yours,

  
Setti D. Warren  
Mayor

RECEIVED  
Newton City Clerk  
2017 AUG -2 PM 2:23  
David A. Olson, CMC  
Newton, MA 02459

1000 Commonwealth Avenue Newton, Massachusetts 02459

[www.newtonma.gov](http://www.newtonma.gov)



DEDICATED TO COMMUNITY EXCELLENCE

**CHRYSE GIBSON**

19 Hampden Terrace  
Newton, MA 02459

**PROFILE*****Organizational Development, Social Action and Strategic Change Leader***

- Consistently successful in helping groups formulate goals, create strategic plans, develop infrastructures, innovative outreach programs and organizational cultures that position each organization as a valuable community asset
- Specializes in building and leading multifaceted organizations through startup, turnaround and high growth cycles

***Areas of Expertise***

- Needs Analysis & Global Organization Building
- Board, Volunteer & Staff Training & Supervision
- Public Policy Research, Development & Advocacy
- Operations Streamlining & Process Improvement
- Mediation, Negotiation & Problem Solving
- Consensus Building & Change Management
- Community Outreach & Partnership Building
- Marketing, Lobbying & Training Presentations

***Selected Professional Experience***

**Oaktree Development**  
**EVP**

**Cambridge, Massachusetts**

Development/design/build firm that specializes in mixed-use smart growth, transit oriented projects utilizing the patented GreenStaxx building technology. Portfolio includes:

- GSX Building System: Project Development, Team Facilitation; Business Development
- Investor Relations: Analysis, strategy, research, presentations
- Marketing/Communications: Corporate & project websites; marketing materials; speaking engagements
- Affordable Housing: Marketing, leasing, wait list maintenance; liaison: DCHD and associated consultants
- Human Resources: overview and supervision
- Finance: Manage annual office budget of \$1.1 million

**Living Ahead**

**Toronto, Ontario**

**President, Organizational Development and Construction Consultant**

**1996 - Present**

Interdependent housing solution to address issues of health/wellness, financial security and connection to community for individuals who are retired or about to retire

- Conceived, designed and developed the interdependent housing program for women in need, as a response to changing economics and demographics
- Created an organizational infrastructure, operational; business and financial systems
- Leveraged construction expertise to provide design and building consultation
- Developed and taught Living Ahead workshop series on interdependent housing for women seniors
- Designed and managed a successful first annual co-housing conference for 200 attendees

**Newton Schools Foundation**  
**Executive Director**

**Newton, Massachusetts**

**2006- 2009**

Educational foundation that raises private monies to support public education, grades K-12

Highlights include:

- Revived Foundation to embrace rapidly changing educational environment, address challenges and reorient the resource development strategy
- Positioned the Foundation as bridge between the private and public sectors in support of public education
- Grew donor base by 30% in the first year and 20% in the second year; instituted multi-year funding
- Doubled the number of activists and volunteers working with the Foundation
- Moved the organization from a deficit to surplus position in one year  
Annual Budget - \$500,000; Endowment - \$1.4 million  
Staff - 2; Volunteers - 52; Board of Directors - 22

**Women's Future Fund**

Toronto, Ontario

**Founding Executive Director**

Federation of 9 national women's charities organizations representing a half a million clients and volunteers across Canada that raised funds through workplace giving

Membership – 9 organizations - National

Annual Budget - \$350,000

Staff – 2

Board of Directors - 10

**Youth Challenge International (YCI)**

Toronto, Ontario

**Executive Director**

Non-government organization committed to youth development through community service in Costa Rica, Guyana and Canada for participants ages 18-25

Annual Budget - \$575,000

Staff – 12

Board of Directors - 12

**OXFAM-CANADA**

Ottawa/Toronto, Ontario

**Senior Director of Canadian Programs**

International development organization dedicated to creating self-sustaining programs in developing communities worldwide by focusing on health security, food security and democratic justice.

- Provided goal setting, strategy, government relations, budget, personnel, conceptual, programmatic and policy leadership to the Canadian program; represented OXFAM-Canada in the international OXFAM family

Scope – National

Annual Budget – \$1.6 million

Offices – 14 – National

Staff – 24

**Sisters Construction**

Vancouver, BC

**Owner/Contractor**

Construction and renovation firm with specialty in kitchens and historic restoration

**Credentials**

Philadelphia College of Art – Sculpture  
U-MASS Amherst, BFA *magna cum laude*  
Licensed Journeyman Carpenter  
Real Estate License, Massachusetts

**Selected Community Work**

Member, Council On Aging Advisory Board (Newton)  
Chair, Carpentry Advisory Cttee, NNHS Career & Tech  
Strategic Advisor, Newton At Home, 2008-10  
Founding Advisor, NPS Innovation Lab  
Vice President, West Toronto Skating Club (CSSA)

Instructor, Carpentry Training Center, Nicaragua  
Board Member, Community Business Resource Center (ON)  
Board Member, Andrew Fleck Childcare Services (Ottawa)  
Founding Member, United Tradeswomen (New York City)

From: Chryse Gibson <cgibson@oakdev.com>  
To: "Susan M. Paley" <SPaley@village-bank.com>  
Subject: Re: FW: Council on Aging  
Date sent: Mon, 17 Jun 2013 12:38:14 -0400  
Copies to: "Ana Gonzalez (agonzalez@newtonma.gov)" <agonzalez@newtonma.gov>, "Jayne Colino (jcolino@newtonma.gov)" <jcolino@newtonma.gov>, "Marian L Knapp (knappml@comcast.net)" <knappml@comcast.net>

---

Ana,

It is nice to meet you - and Susan, thank you for your kind words. Susan does me honor by suggesting that I might be able to make a contribution to the Council on Aging. I'm not sure but my work on interdependent housing for women could be of interest. I would very much like an opportunity to talk with you about the work of the Council as well as my concept, Living Ahead.

I live in Newton and work in Cambridge so mornings are often good for me. The next couple of weeks are flexible with the exception of Monday morning, July 1st. Is there a time that we can spend 30 minutes or so?

I look forward to hearing from you - and thank you.

Chryse.

On Mon, Jun 17, 2013 at 9:24 AM, Susan M. Paley <SPaley@village-bank.com> wrote:

Good morning, Ana. It was great seeing you at the Highlands Bandstand Ribbon Cutting on Friday evening!

I am attaching the resume of Chryse Gibson who is interested in pursuing an open spot on the Council of Aging's Board of Advisors. She has some great experience in terms of the creation of "liveable communities" which the COA is very interested in. Also, her extensive experience in the construction and development industry is of great interest to us.

I am copying this to Chryse by way of introducing you, and I hope that perhaps you two can get together and begin the process of introducing Chryse to the Council.

Chryse, thank you for your interest in serving.

Susan M. Paley

Vice President, Community Relations

The Village Bank

Phone: 617-340-1204

Fax: 617-467-1804

This e-mail message is intended for the sole use of the addressee and may contain confidential information. If you are not the intended recipient or otherwise authorized to view such information, you are hereby notified that



SETTI D. WARREN  
MAYOR

City of Newton, Massachusetts  
Office of the Mayor

#236-17

Telephone  
(617) 796-1100

Facsimile  
(617) 796-1113

TDD/TTY  
(617) 796-1089

E-mail  
swarren@newtonma.gov

Honorable City Council  
Newton City Hall  
1000 Commonwealth Avenue  
Newton, MA 02459


RECEIVED  
Newton City Clerk  
2017 JUL 12 PM 2:25  
David A. Olson, Clerk  
Newton, MA 02459

Ladies and Gentlemen:

I am pleased to reappoint Edward Marple of 12 Ohio Avenue, Newton as a member of the Biosafety Committee. His term of office shall expire on September 30, 2019 and his appointment is subject to your confirmation.

Thank you for your attention to this matter.

Very truly yours,



Mayor

1000 Commonwealth Avenue Newton, Massachusetts 02459

[www.newtonma.gov](http://www.newtonma.gov)



DEDICATED TO COMMUNITY EXCELLENCE

**Edward W. Marple**

12 Ohio Ave, Newton, MA 02464 |

---

**EXPERIENCE**

---

**Acworth Pharmaceuticals, Inc.** Newton, MA 2016 – present

Co-Founder &amp; CEO

*Acworth Pharmaceuticals was established in December 2016 to in-license certain oncology technology from UMass Medical School. The Company is pursuing an exclusive license to IP around a novel protein therapeutic candidate to treat cancer.*

- Obtained an exclusive option to license patents around a novel protein for the treatment of cancer. The DKK family of proteins are being explored by several biotech and pharma companies as treatments for cancer. The DKK technology the Company is seeking to license is unique, has demonstrated preclinical activity in PDX xenograft models, and extensive mechanism of action data.
- Acworth is seeking to raise \$2.0M seed capital to fund the advanced preclinical development of the technology, expand its IP portfolio, and formalize collaborations with research partners.

---

**Blue Sky Biotech, Inc.** (Acquired by LakePharma, Inc.) Worcester, MA 2013 – 2016

President &amp; CEO

*LakePharma – Blue Sky Biotech – is a private equity-backed, nearly 100-person Contract Research Organization (CRO) offering biologics R&D services from gene-synthesis to purified protein/antibody production, and customized assays including radio-labeling, for global pharmaceutical, biotechnology, and other life science customers.*

- Led successful strategic partnering process to find M&A partner for Blue Sky to add scale, technology, geographic presence.
- Expanded financial analysis to improve Blue Sky's margins with process and operational improvements which led to increased profitability, increasing EBITDA margins, growing annualized revenues of a record breaking \$8+M with long-term FTE agreements, and satisfied customers in April 2016.
- Improved quality of services. Developed and implemented new quality processes following GLP standards to reverse trend of customer departures due to poor quality. Focused the mix of services and technologies to meet key customer demands, changed lab and company culture with a greater emphasis on accountability, quality, customer communication, excellent science, and rigorous execution.
- Established sustainable, quality operational capabilities leading to faster turn-around time, and greater customer satisfaction. Improved customer retention and reduced repeat rates (rework). Increased molecular biology quality/through-put in DNA production to be world-class leading platform, expanded Assay Services technology platform in fastest growing business unit.
- Built a collaborative management team, with shared goals, committed to growth.

---

**Independent Biotech Consultant,** Newton, MA 2012 – 2013

Life Science Business and Corporate Development

- Provided strategic and operational consulting services to leading contract research service company.
- Led business and corporate development activities, including term sheet development and initiating partnering discussions, for a private biotechnology company in discussions with large life sciences companies for new product licensing opportunities related to reagents and oncology therapeutics.
- Developed collaboration and new product strategy leveraging existing technology and manufacturing capacity for a private equity-backed medical products company with unique regulated manufacturing technologies in the radiopharmacy space.

---

**Xcellerex, Inc.** (Acquired by GE Healthcare), Marlborough, MA

Chief Business Development Officer – 2010 - 2012

Vice President, Business Development – 2009 - 2010

Sr. Director, Business Development – 2008 - 2009

*Xcellerex sells biomanufacturing equipment and related supplies and contract biomanufacturing services for the manufacture of large molecule drugs and vaccines.*

- Led corporate development. Led partnering discussions to bring novel technologies into the company and create new channels for revenue; looked to out-license/sell non-core assets.
- One of three senior executives: together with CEO and CFO presented the corporate strategy to potential strategic investors and acquirors.
- Developed corporate strategy with CEO to re-focus the company's operations to maximize value and shareholder return; led to almost doubling of revenue from 2010-2011; first year EBITDA positive.
- Acted as interim Chief Commercial Officer for five months leading sales and marketing teams to improve coordination between operations and marketing, and drive sales.
- Led negotiations with customers on long-term supply agreements for consumable products to protect and ensure long-term revenue stream and protect margins.
- Responsible for deal structures for partnerships that included obtaining equity, royalties, and milestones from customers who also paid for biomanufacturing services.
- Served as CFO for six months prior to hiring new CFO and promotion to CBO. Oversaw finance and BD teams.

---

**Point Therapeutics, Inc.,** Boston, MA

Vice President, Business Development – 2004 - 2007

*Point Therapeutics was developing a novel family of small molecule drugs, including its lead candidate for cancer.*

- Led the business development operations around lead oncology asset in Phase 2 and 3 clinical development; core member of the corporate business team of CEO, General Counsel, and CFO.
- Initiated and managed high level relationships with over three dozen pharmaceutical and biotechnology companies from the US, Europe, and Japan. Included market assessment, term sheets, co-development and due diligence leadership.

---

**Beyond Genomics, Inc.,** Waltham, MA

Director, Marketing - Strategy – 2001 - 2004

- Formulated key deal terms for partnerships including intellectual property, term/termination, upfront and milestones. Pilot study deals completed with Novartis, AstraZeneca, and GlaxoSmithKline.
- Developed strategy, including IP, to strengthen position as the leading Systems Biology company by enhancing leadership position in proteomics, metabolomics, transcriptomics and integration of clinical data. Implemented publications strategy with Chief Technology Officer leading to high-visibility participation and leadership in over 60 conferences in 18 months to meet outreach targets and support company's Systems Biology leadership status.

---

**Eli Lilly and Company,** Indianapolis, IN

Senior Associate, Business Development – 1999 - 2001

- Led teams of MDs, PhDs, and MBAs developing strategic partnerships in multiple disease areas with focus on cardiovascular diseases. Received Lilly's Corporate Business Development Award in 2001 for cardiovascular product in-licensing deal structure with Sankyo.
- Managed, structured and negotiated strategic alliances, licenses, co-promotion/co-marketing, and development opportunities with Japanese pharma, US biotech and US pharma companies.

---

**Prudential HealthCare,** New York, NY

Account Executive – 1991 - 1997

- Sales and marketing representative in Prudential's managed care division for NY, NJ and CT.
- Led customer retention programs, and represented sales team on drug formulary committee.

---

**Education****University of Virginia, Darden Graduate School of Business Administration,** Charlottesville, VA

MBA, 1999

**Harvard College,** Cambridge, MA

A.B., 1991



## Why are you interested in serving on a board or commission?

---

I have enjoyed being a part of the Biosafety Committee for the past several years, and think that the Committee and its role in helping Newton ensure a safe biotechnology business presence in Newton is essential. I also was very happy to see that the City Council passed the recent ordinance revisions to ensure future safety of the community, but also enable growth of the biotech sector in Newton. The process of starting a biotech business, and my past experience working in Worcester running a CRO business, has given me key, relevant experience related to the mission of the Biosafety Committee, and provided insights into how our community can be better served by such a committee. My interest in seeing Newton expand its biotech footprint is both personal as a resident, but also essential if Newton is going to be a peer and leader for life science growth in the future which is so critical for the city and surrounding communities. Life Science research and business investment will continue to grow, and I'd like to see Newton be best positioned to capture much of the research and development investment as possible. That includes building robust processes, streamlined regulations and oversight, to ensure safe and long-term business growth of biotech businesses in the City. The types of jobs biotech businesses bring to a community range from world class PhD scientists, to employees who work late at night or early in the morning ensuring labs are clean and ready for the next scientific breakthrough. So, it's that background and interest that leads me to welcome the opportunity to serve again if possible.

---

[Upload a Resume](#)



SETTI D. WARREN  
MAYOR

City of Newton, Massachusetts  
Office of the Mayor

#237-17

Telephone  
(617) 796-1100

Facsimile  
(617) 796-1113

TDD/TTY  
(617) 796-1089

E-mail  
swarren@newtonma.gov

Honorable City Council  
Newton City Hall  
1000 Commonwealth Avenue  
Newton, MA 02459


RECEIVED  
Newton City Clerk  
2017 JUL 12 PM 2:25  
David A. Olson, Clerk  
Newton, MA 02459

Ladies and Gentlemen:

I am pleased to reappoint John J. Schwartz of 200 Upland Road, Newton as a member of the Biosafety Committee. His term of office shall expire on September 30, 2020 and his appointment is subject to your confirmation.

Thank you for your attention to this matter.

Very truly yours,



Setti D. Warren

Mayor

1000 Commonwealth Avenue Newton, Massachusetts 02459

[www.newtonma.gov](http://www.newtonma.gov)



DEDICATED TO COMMUNITY EXCELLENCE

**MIT VENTURE MENTORING SERVICE (VMS), Boston, MA****2001 – Present**

*VMS is a pro-bono organization that supports innovation and entrepreneurial activity throughout MIT. VMS supports innovation and entrepreneurial activity throughout the MIT community by matching both prospective and experienced entrepreneurs with skilled volunteer mentors. VMS complements and works cooperatively with the many MIT centers and programs promoting entrepreneurship and providing many resources to encourage formation of businesses and to move technological knowledge from the laboratory to the marketplace. [www.vms.mit.edu](http://www.vms.mit.edu)*

***Venture Mentor***

Business Mentor for MIT companies developing:

- Clinical diagnostics and personalized medicine
- Therapeutics
- Combination products
- Genomic engineering and synthetic biology
- Life science research tools
- Alternative and renewable energy

**BOSTON HARBOR ANGELS, Boston, MA****2002 – 2009**

*Boston Harbor Angels is one of the most active angel groups in the country with over 35 deals invested.*

***Member of the Executive Committee, Head of Membership, Private Equity Investor***

- Invested mentored and advised a therapeutic and a medical device company in raising over \$3 million.
- Worked to build deal momentum and set up and close the Series 'A' round for a self-regulating insulin drug delivery company that was ultimately acquired by Merck for \$500 million, which was a 25x return on investment.

**STATGE 1 STRATEGIES, LLC, Boston, Massachusetts****2004 – 2008**

*Private, consulting firm that had clients in medical imaging, life sciences and small medical device companies. Drafted business strategy plans, negotiated university licenses, performed competitive intelligence, business development, market mapping and development, investment due diligence and designed plans for structured finance for start-ups.*

***Life Sciences Business Consultant***

- Assisted a Harvard University oncology spinout in negotiating a license, developing proper corporate governance structures, funding strategy, business and technical development plans.
- Significantly increased revenues at a research biologics company by developing a new marketing plan.
- Performed competitive intelligence for a major pharmaceutical company looking to introduce their blockbuster first in class type-2 diabetes drug, Januvia \$2.4BB sales per year.
- Performed market analysis for several cardiovascular imaging device and drug delivery companies.
- Engaged by a board of directors and investors to perform a turnaround analysis for a failing oncology personalized medicine company.
- Assisted the Plaintiff of a \$400 million lawsuit by serving as a non-testifying expert witness in a dispute between a limited partner (the Plaintiff a large biotechnology company) and a general partner of a large venture capital fund. The matter related to a dispute over the adequacy of general partner due diligence in a specific fund investment.

**BIOTell, INC.**, Boston, MA

2002 – 2009

*BIOTell, Inc was a start up company that, in collaboration with the University of Massachusetts at Dartmouth, developed a novel surface Plasmon resonance biosensor used to detect botulinum toxin A.*

**Director, Assay Development**

- Secured over \$1.5 million by co-authoring 2 successful SBIR grants for the rapid detection of botulinum toxins using a high sensitivity SPR sensor.
- Developed and implemented novel surface plasmon resonance (SPR) biosensor surface chemistries, biochemical assays and sample preparation techniques.
- Designed, engineered/chemically modified proteins and peptides and performed biochemical assays demonstrating the sensitivity and specificity of the company's chip-based SPR detection technology. Worked to develop and manage University of Massachusetts at Dartmouth collaborators, troubleshoot and manage technology project timeline

**EngeneOS, Inc.**, Boston, MA

2000 – 2002

*EngeneOS, Inc was a novel bio-nanotechnology company positioned at the intersection of information technology, physics, chemistry and molecular biology. Raised \$7 million for initial lab set up hired a staff of 25, biopharmaceutical drug design and discovery, technical development and IP portfolio development.*

**Co-Founder, Principal Scientist**

- Developed technology, drafted core patents and claim sets, developed advanced technology prototypes, established 2 wet labs, with regulatory licensing, from the ground up.
- Managed 4 Ph.D.'s and two technicians.
- EngeneOS was split into two companies, ADNEXUS, a biopharmaceutical company, and Epitome Biosystems, a protein biosensor company. ADNEXUS was acquired by Bristol Myers for \$470 million in 2007, a 12x return on investment and the Epitome by Millipore in for \$35 million 2009, which was 5x return on investment.

**M.I.T. Media Laboratory Nanomedia Group**, Boston, MA

1999 – 2002

*Visiting Scientist, Co-Principal Investigator, \$1.7 million DARPA Grant*

**M.I.T. Center for Biomedical Engineering**, Boston, MA

1999 – 2002

*Research Scientist, Co-Principal Investigator, \$900,000 NSF Grant*

**M.I.T. Department of Biology/Harvard Medical School**, Boston, MA

1991 – 1998

*Postdoctoral Research fellow, multiple NIH fellowships*

**EDUCATION**

**NEW YORK MEDICAL COLLEGE**; Ph.D. in Biochemistry and Molecular Biology, 1992.  
Developed two effective human clinical nucleic acid-based diagnostic tests for Lyme Disease.

**NEW YORK MEDICAL COLLEGE**; M.S. Biochemistry, 1987.  
Research and experimentation on bacterial ribosomal RNA and protein translation initiation.

**University of Massachusetts at Amherst**; B.S. Microbiology/ Philosophy Minor, 1985.

## Application Form

### Profile

John

First Name

J

Middle Initial

Schwartz

Last Name

Email Address

Home Address

City

Suite or Apt

State

Postal Code

### What Ward do you live in?

☒ Ward 2

Primary Phone

Alternate Phone

AcuityBio, Corporation

Employer

CEO

Job Title

### Which Boards would you like to apply for?

Biosafety Committee: For Review

### Interests & Experiences

Please tell us about yourself and why you want to serve.

### Why are you interested in serving on a board or commission?

I have been an Newton resident for >25 years. In that time I have been an academic at MIT, entrepreneur. In my laboratory at MIT and in several of my companies I have served as safety officer. I have been privileged to participate in keeping our city safe as a member of the current rDNA Board. I would like to continue to serve.



SETTI D. WARREN  
MAYOR

City of Newton, Massachusetts  
Office of the Mayor

#242-17

Telephone  
(617) 796-1100

Facsimile  
(617) 796-1113

TDD/TTY  
(617) 796-1089

E-mail  
swarren@newtonma.gov

RECEIVED  
Newton City Clerk

2017 JUL 12 PM 2:25

David A. Olson, Clerk  
Newton, MA 02459


Honorable City Council  
Newton City Hall  
1000 Commonwealth Avenue  
Newton, MA 02459

Ladies and Gentlemen:

I am pleased to reappoint Dana Hanson of 64 Kingswood Road, Auburndale as a member of the Library Trustee. Her term of office shall expire on June 30, 2021 and her appointment is subject to your confirmation.

Thank you for your attention to this matter.

Very truly yours,



Setti D. Warren

Mayor

1000 Commonwealth Avenue Newton, Massachusetts 02459

[www.newtonma.gov](http://www.newtonma.gov)



DEDICATED TO COMMUNITY EXCELLENCE

# DANA HANSON

#242-17

64 Kingswood Rd, Auburndale, MA 02466 |

## PROFESSIONAL SUMMARY

Energetic and dedicated Newton community volunteer. Passionate interest and involvement in children's and youth programming and services in Newton. Highly motivated and skilled in project management, planning, promoting, and running organizations, programs, and community events for infants through senior citizens in the City of Newton.

## TOOL KIT

Constant Contact, Lucidpress, WordPress, Blogger,  
MailChimp, SurveyMonkey, DonorSnap, GoDaddy, Wix,  
iMovie, Photoshop Elements

Facebook, Twitter, Instagram, LinkedIn, Pinterest, Word,  
Excel, PowerPoint, Google Docs/Groups, PayPal, Prezi,  
Doodle

## COMMUNITY ENGAGEMENT

MARCH 2011-CURRENT

*Board of Trustees Newton Free Library |*

- Help ensure the library fulfills its mission to provide educational, cultural, and recreational enrichment.
- Promote programs and services of the library in the community.
- Chair annual Spring Fling fundraising gala.
- Served on search committee for Director of the library.

JUNE 2009-CURRENT

*Board of Directors, President Auburndale Community Library |*

- Spearheaded neighborhood effort to re-open shuttered community library.
- Responsible for recruitment, scheduling, and management of library volunteers.
- Train and work with youth volunteers. Work collaboratively with youth to identify youth-led projects and programs.
- Develop and promote library's programs and activities based on community needs and interests, with a particular emphasis on children's/teen programming.
- Write bi-weekly email newsletter and promote events on social media.

SEPTEMBER 2006-CURRENT

*FA Day Middle School & Burr Middle School PTO President, Event Chair, School Council |*

- Create, manage, and promote year-round projects and events. Chair meetings, committees, and events.
- Communicate via newsletters, social media, and public speaking.
- Work with Principal, teachers and administrators to ensure smooth operations at school. Successfully managed communications as PTO president during principal transition at Burr Elementary.
- Address and resolve parent problems and concerns in a tactful and timely manner.
- Lead projects: Website manager at FA Day, Gift for Burr Annual Fund, World Cultures Celebrations, Respect for Human Differences, Burr Boston Buddies, Burr Community Gardening, programs promoting reading and literacy.

*First Unitarian Society in Newton Program Coordinator, Youth Advisor, Teacher |*

- Longest-serving high school youth group advisor in our congregation (over 10 years). Current member of Youth Programming Circle. Served on New England regional District Youth Steering Committee with youth and adults from around the state.
- Currently oversee and support 16 youth Sunday School teachers--hold monthly check-ins.
- Work with and advise youth on annual FUSN Youth Coffeehouse--a youth-produced concert to benefit Communities Without Borders.
- Attend youth conferences and programs with teens--emphasis on social justice, anti-racism, community service, and youth leadership development.
- Administered annual Coming of Age program for 20+ eighth graders and their adult mentors for three years. Responsible for all elements of program management, including scheduling, volunteer recruitment, curriculum, and communications.
- Long-time member of FUSN Religious Education Council. Served on search committee for paid staff Youth Program Coordinators and Directors of Religious Education.
- Teach regular weekly Sunday school classes for grades 3 through 8.

SEPTEMBER 2004-JUNE 2008

*Burr Cooperative Nursey School Board of Directors, President |*

- Worked with the director of the school to develop school policies and implement school operations.
- Led parent volunteers in marketing, fundraising, and general maintenance of the school.

## OTHER ACTIVITIES

.....  
Waltham Track Club volunteer coach, Brown University Area Alumni Interviewing Co-Chair, Principal selection small group interview committee Newton North High School 2016, Showa University Part Time Faculty Fall 2015, Newton Cultural Alliance gala, Auburndale Community Association Rove the Cove, Understanding Our Differences, Islington Peninsula neighborhood events, Ward 4 community involvement, Newton Serves

## EDUCATION

1998

*Master of Science: Environmental Science and Engineering*

Harvard School of Public Health, Boston, MA

1993

*Bachelor of Arts: Environmental Studies*

Brown University, Providence, RI

## PRIOR WORK EXPERIENCE

.....  
Prior to starting my family in 2000, I worked in the field of public health and industrial hygiene (worker safety). I conducted research and/or health and safety evaluations in workplaces ranging from construction sites/heavy manufacturing, to healthcare/laboratory settings, to schools and commercial office buildings.

- Environmental Health & Engineering, Associate
- UMASS Lowell Construction Occupational Health Project, Researcher
- RI Dept of Health, Office of Environmental Affairs, Contract Employee